For more information, view the JAMA Oncology article available at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2776761
Category: Newsletter Articles & Posts
Permanent link to this article: https://inheritedcancer.net/post42821/
ICARE Social Media Post April 2021
Addressing Racial Disparities in Breast Cancer Clinical Trial Enrollment
ICARE Social Media Post April 2021
Addressing Racial Disparities in Breast Cancer Clinical Trial Enrollment
For more information, read the recently published ASCO Daily News editorial led by ๐๐ฟ. ๐ฆ๐ผ๐ป๐๐ฎ ๐ฅ๐ฒ๐ถ๐ฑ from Vanderbilt University Medical Center, which focused on racial disparities in breast cancer clinical trial enrollment: https://dailynews.ascopubs.org/do/10.1200/ADN.21.200499/full/
Permanent link to this article: https://inheritedcancer.net/post42321/
ICARE Social Media Post April 2021
Komen Disparities Resource
ICARE Social Media Post April 2021
Komen Disparities Resource
Check out Susan G. Komen’s “๐๐ป๐ผ๐ ๐ฌ๐ผ๐๐ฟ ๐๐ถ๐๐๐ผ๐ฟ๐, ๐๐ป๐ผ๐ ๐ฌ๐ผ๐๐ฟ ๐ฅ๐ถ๐๐ธ” resource, which outlines disparities in breast cancer, how to understand your risk, and recommended screening and management practices. To learn more, please visit: ๐ https://www.komen.org/about-komen/our-impact/breast-cancer/health-equities-initiative/know-your-history/ ๐ https://blog.komen.org/news/black-history-month/
Permanent link to this article: https://inheritedcancer.net/post42021/
ICARE Social Media Post April 2021
Olaparib for Metastatic Breast Cancer
ICARE Social Media Post April 2021
Olaparib for Metastatic Breast Cancer
For more information, view the article at: https://ascopubs.org/doi/abs/10.1200/JCO.20.02151
Permanent link to this article: https://inheritedcancer.net/post41321/
ICARE Social Media Post April 2021
Winter 2021 Ask the Expert
ICARE Social Media Post April 2021
Winter 2021 Ask the Expert
In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Rebecca Smith explains how a genetic change (or mutation) is classified as pathogenic or benign. Check out Dr. Smith’s full response in our Winter 2021 newsletter at: https://inheritedcancer.net/newsletters/
Permanent link to this article: https://inheritedcancer.net/post40921/
ICARE Social Media Post April 2021
Fruits and Vegetables Lower Mortality
ICARE Social Media Post April 2021
Fruits and Vegetables Lower Mortality
For further information, view the article available at:https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.048996
Permanent link to this article: https://inheritedcancer.net/post40621/
ICARE Social Media Post April 2021
Family Communication of Genetic Test Results Among Women with Inherited Breast Cancer Genes
ICARE Social Media Post April 2021
Family Communication of Genetic Test Results Among Women with Inherited Breast Cancer Genes
Check out a recent article led by the ICARE team, published in the Journal of Genetic Counseling, outlining family communication of genetic test results among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Check out the full article at: https://onlinelibrary.wiley.com/doi/full/10.1002/jgc4.1356
Permanent link to this article: https://inheritedcancer.net/post40221/
ICARE Social Media Post March 2021
STK11: Cancer Risks and Risk Management
ICARE Social Media Post March 2021
STK11: Cancer Risks and Risk Management
Gene: STK11 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 Women:Breast cancer risk: Elevated at 40-60% – Recommend annual mammogram and breast MRI starting at around age 30. Ovarian tumor risk (typically benign sex cord/Sertoli cell tumors): Elevated at 18-21% – Recommend annual pelvic exam starting at …
Permanent link to this article: https://inheritedcancer.net/post33021/
ICARE Social Media Post March 2021
MUTYH: Cancer Risks and Risk Management
ICARE Social Media Post March 2021
MUTYH: Cancer Risks and Risk Management
Gene: MUTYH Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 Men & women with two mutations in MUTYH:Colon cancer risk: High risk – Recommend colonoscopy every 1-2 years beginning at age 25-30; colectomy considered based on polyp burden and age. Duodenal cancer risk: Elevated – Consider baseline …
Permanent link to this article: https://inheritedcancer.net/post32321/
ICARE Social Media Post March 2021
Winter 2021 Community Spotlight
ICARE Social Media Post March 2021
Winter 2021 Community Spotlight
In every ICARE newsletter we feature a ๐ฐ๐ผ๐บ๐บ๐๐ป๐ถ๐๐ ๐๐ฝ๐ผ๐๐น๐ถ๐ด๐ต๐ to share their experience with inherited cancer. In the latest edition, Dave Dubin, co-founder of AliveAndKickn, shares his experience with Lynch Syndrome. Check out his full story at: https://inheritedcancer.net/community-spotlight/
Permanent link to this article: https://inheritedcancer.net/post31921/
ICARE Social Media Post March 2021
APC: Cancer Risks and Risk Management
ICARE Social Media Post March 2021
APC: Cancer Risks and Risk Management
๐๐ฒ๐ป๐ฒ: ๐๐ฃ๐ Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 ๐ ๐ฒ๐ป & ๐ช๐ผ๐บ๐ฒ๐ป:๐๐๐ mutation leading to classic form of Familial Adenomatous Polyposis (FAP):Colorectal cancer risk: >99% if untreated – Treatment is based on polyp burden and includes proctocolectomy (with subsequent endoscopic screening of the ileal pouch) or …
Permanent link to this article: https://inheritedcancer.net/post31621/
ICARE Social Media Post March 2021
Colorectal Cancer Risk Assessment Tool
ICARE Social Media Post March 2021
Colorectal Cancer Risk Assessment Tool
In honor of ๐๐ผ๐น๐ผ๐ฟ๐ฒ๐ฐ๐๐ฎ๐น ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐๐๐ฎ๐ฟ๐ฒ๐ป๐ฒ๐๐ ๐ ๐ผ๐ป๐๐ต, we wanted to highlight the National Cancer Institute’s Colorectal Cancer Risk Assessment Tool (CCRAT) designed for healthcare providers to use with select patients to estimate the risk of colorectal cancer. You may access the tool at https://ccrisktool.cancer.gov
Permanent link to this article: https://inheritedcancer.net/post31221/
ICARE Social Media Post March 2021
Three Articles: Breast Cancer Risks
ICARE Social Media Post March 2021
Three Articles: Breast Cancer Risks
For additional information about the: ใUS-based study, visit: https://www.nejm.org/doi/full/10.1056/nejmoa2005936 ใInternational study, visit: https://www.nejm.org/doi/full/10.1056/nejmoa1913948 ใAccompanying editorial: https://www.nejm.org/doi/full/10.1056/NEJMe2035083
Permanent link to this article: https://inheritedcancer.net/post30921/
ICARE Social Media Post March 2021
Breastfeeding and the Risk of Epithelial Ovarian Cancer Among Women with A BRCA1 or BRCA2 Mutation
ICARE Social Media Post March 2021
Breastfeeding and the Risk of Epithelial Ovarian Cancer Among Women with A BRCA1 or BRCA2 Mutation
For further information, view the article available at: https://www.gynecologiconcology-online.net/action/showPdf?pii=S0090-8258%2820%2933947-0
Permanent link to this article: https://inheritedcancer.net/post30221/
ICARE Social Media Post February 2021
Olaparib and Invasive Disease-Free Survival in Patients with BRCA, High-Risk, Early Breast Cancer
ICARE Social Media Post February 2021
Olaparib and Invasive Disease-Free Survival in Patients with BRCA, High-Risk, Early Breast Cancer
For additional information visit: https://www.onclive.com/view/adjuvant-olaparib-showcases-idfs-improvement-in-brca-high-risk-early-breast-cancer
Permanent link to this article: https://inheritedcancer.net/post22321/
Permanent link to this article: https://inheritedcancer.net/2nlw2021/
Permanent link to this article: https://inheritedcancer.net/1nlw2021/
ICARE Newsletter Winter 2021
Exploring Disparities Among Those with Inherited Cancers
ICARE Newsletter Winter 2021
Exploring Disparities Among Those with Inherited Cancers
It has never been more urgent to ensure that advances in genomic technologies do not further widen existing cancer health disparities. In the fall of 2020, the American Association for Cancer Research (AACR) put forth a report focused on cancer health disparities, in which they highlighted several issues.1 Notably, disparities in inherited cancer care were …
Permanent link to this article: https://inheritedcancer.net/5nlw2021/
ICARE Newsletter Winter 2021
Study Suggests Low Yield of MRI Surveillance After Bilateral Mastectomy
ICARE Newsletter Winter 2021
Study Suggests Low Yield of MRI Surveillance After Bilateral Mastectomy
A study of 159 women, including BRCA1/2 carriers, who had a bilateral mastectomy with reconstruction and underwent breast MRI screening, showed few women had detection of breast cancer through MRI after their bilateral mastectomy. These results support the recommendation that BRCA1/2 carriers with or without breast cancer who have a bilateral mastectomy with reconstruction do …
Permanent link to this article: https://inheritedcancer.net/8nlw2021/
ICARE Newsletter Winter 2021
Community Spotlight
ICARE Newsletter Winter 2021
Community Spotlight
My genes donโt define me. I am AliveAndKickn. Pretty bold statement. AliveAndKickn is more than just a name. Itโs a way of life. I joke that Lynch Syndrome is the genetic predisposition to colon cancer, endometrial cancer, other cancersโฆand soccer. But thatโs just me. Besides half a dozen surgeries since 1997, I have and still play and coach the game I love. …
Permanent link to this article: https://inheritedcancer.net/spotlightnlw2021/
ICARE Newsletter Winter 2021
Learning You Have a Mutation in an Inherited Cancer Gene: Whatโs Next?
ICARE Newsletter Winter 2021
Learning You Have a Mutation in an Inherited Cancer Gene: Whatโs Next?
The benefits achieved through genetic testing for inherited cancer only happen by acting upon the results. This can be through guiding cancer treatment, receiving appropriate cancer risk management strategies, and sharing results with at-risk family members so they too can benefit from this information. We recently reported on results of our study, made possible through …
Permanent link to this article: https://inheritedcancer.net/6nlw2021/
ICARE Newsletter Winter 2021
CHEK2 is NOT a Li-Fraumeni Syndrome Gene
ICARE Newsletter Winter 2021
CHEK2 is NOT a Li-Fraumeni Syndrome Gene
An old study back in 1999 suggested that CHEK2 may be a Li-Fraumeni Syndrome gene.1 However, a subsequent report in 2002 clearly refuted this original assertion, and based on additional data and analysis concluded that โโฆ it is very unlikely that CHEK2 is an alternative Li-Fraumeni Syndrome susceptibility gene.โ2 Another subsequent report in 2008 based …
Permanent link to this article: https://inheritedcancer.net/4nlw2021/
ICARE Newsletter Winter 2021
Assessing How Pregnancy and Breastfeeding May Affect Cancer Risks in BRCA Carriers
ICARE Newsletter Winter 2021
Assessing How Pregnancy and Breastfeeding May Affect Cancer Risks in BRCA Carriers
Results of a recently published study suggested that pregnancy after breast cancer in BRCA carriers does not lead to a worse outcome in women or their fetuses.1 This information is reassuring for BRCA carriers who have had a prior diagnosis of breast cancer and are considering having children. In another study among female BRCA carriers …
Permanent link to this article: https://inheritedcancer.net/3nlw2021/
ICARE Newsletter Winter 2021
Ask the Expert
ICARE Newsletter Winter 2021
Ask the Expert
In each newsletter, we give participants the opportunity to have their questions addressed by experts in the field. This question was addressed by Rebecca Smith, PhD, Laboratory Director at Genetics Associates, Inc. with over 20 years of experience in biomedical research and 7 years of experience in clinical laboratory diagnostics. If you have a question …
Permanent link to this article: https://inheritedcancer.net/9nlw2021/
ICARE Newsletter Winter 2021
Inherited Cancer Treatment: Updates and Relevant Policies
ICARE Newsletter Winter 2021
Inherited Cancer Treatment: Updates and Relevant Policies
Over the last several months, the American Society of Clinical Oncology published a number of guidelines related to the use of PARP inhibitors among those with BRCA-associated cancers, including guidelines focused on ovarian cancer,1 metastatic pancreatic cancer,2 and breast cancer.3 Additionally, costs of drugs also have great potential to influence policy, highlighting the importance of …
Permanent link to this article: https://inheritedcancer.net/7nlw2021/
ICARE Social Media Post February 2021
Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM Carriers
ICARE Social Media Post February 2021
Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM Carriers
Our team recently published “Sharing Genetic Test Results with Family Members of ๐๐๐๐, ๐๐๐๐2, ๐๐๐๐2, and ๐๐๐ Carriers” in ๐๐ข๐ต๐ช๐ฆ๐ฏ๐ต ๐๐ฅ๐ถ๐ค๐ข๐ต๐ช๐ฐ๐ฏ ๐ข๐ฏ๐ฅ ๐๐ฐ๐ถ๐ฏ๐ด๐ฆ๐ญ๐ช๐ฏ๐จ Special Issue on Genetics. View the article available at:https://www.sciencedirect.com/science/article/pii/S0738399120306832 Challenges and barriers to family sharing included concern for family members’ reactions, complexities of information, lack of closeness, perceived relevance, & emotional impact. …
Permanent link to this article: https://inheritedcancer.net/post20821/
ICARE Social Media Post February 2021
Strategies to Enhance the Identification of Hereditary Breast Cancer Gene Carriers
ICARE Social Media Post February 2021
Strategies to Enhance the Identification of Hereditary Breast Cancer Gene Carriers
Check out a recent review article led by the ICARE team, published in ๐๐น๐ฑ๐ฆ๐ณ๐ต ๐๐ฆ๐ท๐ช๐ฆ๐ธ ๐ฐ๐ง ๐๐ฐ๐ญ๐ฆ๐ค๐ถ๐ญ๐ข๐ณ ๐๐ช๐ข๐จ๐ฏ๐ฐ๐ด๐ต๐ช๐ค๐ด, outlining strategies to improve the identification of inherited breast cancer gene carriers. Check out the full article at: https://www.tandfonline.com/doi/pdf/10.1080/14737159.2020.1816829?needAccess=true
Permanent link to this article: https://inheritedcancer.net/post20221/
ICARE Social Media Post January 2021
Male Breast Cancer Coalition (MBCC)
ICARE Social Media Post January 2021
Male Breast Cancer Coalition (MBCC)
The Male Breast Cancer Coalition (MBCC) shares stories from male breast cancer survivors all over the world. To learn more and find resources for affected men and their families, please visit https://malebreastcancercoalition.org/. MBCC also developed printable and shareable cards in over 20 languages outlining the proper way to do self-breast exams for both men and …
Permanent link to this article: https://inheritedcancer.net/post12621/
ICARE Social Media Post January 2021
COVID-19 Vaccine Myths
ICARE Social Media Post January 2021
COVID-19 Vaccine Myths
Although we don’t typically post on vaccines, given the public health importance of the COVID-19 vaccine and the questions we have received related to whether the vaccine could change one’s DNA, we wanted to provide some information and resources to address some of the most common myths about this vaccine. For more information, watch the …
Permanent link to this article: https://inheritedcancer.net/post12221/
ICARE Social Media Post January 2021
Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM
ICARE Social Media Post January 2021
Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM
Check out a new article by the ICARE team, published in Patient Education and Counseling, evaluating the motivators and barriers to sharing personal genetic test results with family members. The article is ๐ณ๐ฟ๐ฒ๐ฒ to access and download ๐๐ป๐๐ถ๐น ๐ ๐ฎ๐ฟ๐ฐ๐ต ๐ฑ๐๐ต at: https://www.sciencedirect.com/science/article/pii/S0738399120306832
Permanent link to this article: https://inheritedcancer.net/post11521/
ICARE Social Media Post January 2021
Qualitative Methods for Refining a Web-Based Educational Tool for Patients Focused on Inherited Cancer Predisposition
ICARE Social Media Post January 2021
Qualitative Methods for Refining a Web-Based Educational Tool for Patients Focused on Inherited Cancer Predisposition
Check out a study led by the ICARE team, published with @SpringerNature in the Journal of Cancer Education, outlining the evaluation and refinement strategies of an interactive web-based tool developed to provide education about inherited cancer risk. Check out a full-text view-only version of the paper at https://rdcu.be/cc8sR or read the abstract at https://pubmed.ncbi.nlm.nih.gov/33400205/ (PMID: …
Permanent link to this article: https://inheritedcancer.net/post11221/
ICARE Social Media Post January 2021
Family Sharing Resources: GeneSHARE
ICARE Social Media Post January 2021
Family Sharing Resources: GeneSHARE
With the tremendous advances in gene-based care among those at risk for inherited cancer, we are trying to develop and improve tools and strategies to make it easier for more people to benefit from genetic testing. We are excited to share with you a free online toolkit called ๐๐ฒ๐ป๐ฒ๐ฆ๐๐๐ฅ๐, which is aimed at helping patients …
Permanent link to this article: https://inheritedcancer.net/post10821/
ICARE Social Media Post January 2021
National Cancer Institute (NCI) Cancer Genetics PDQ
ICARE Social Media Post January 2021
National Cancer Institute (NCI) Cancer Genetics PDQ
For further information, check out the National Cancer Institute’s PDQยฎ Cancer Genetics Summary available at: https://www.cancer.gov/publications/pdq/information-summaries/genetics
Permanent link to this article: https://inheritedcancer.net/post10521/
ICARE Social Media Post December 2020
Genetic Testing in Women with Breast Cancer
ICARE Social Media Post December 2020
Genetic Testing in Women with Breast Cancer
Approximately 4,000 women with breast cancer were tested for mutations in nine breast cancer genes – 6.2% had mutations in at least one of the nine genes, and 2.7% had mutations in either ๐ฝ๐๐พ๐ผ1 or ๐ฝ๐๐พ๐ผ2. Comparisons between women who did versus did not meet National Comprehensive Cancer Network (NCCN) guidelines for testing showed that: …
Permanent link to this article: https://inheritedcancer.net/post122920/
ICARE Social Media Post December 2020
Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
ICARE Social Media Post December 2020
Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
For further information, read the article available at: https://jnccn.org/…/journals/jnccn/18/11/article-p1528.xml
Permanent link to this article: https://inheritedcancer.net/post122220/
ICARE Social Media Post December 2020
CHEK2 is NOT a Li-Fraumeni Syndrome Gene
ICARE Social Media Post December 2020
CHEK2 is NOT a Li-Fraumeni Syndrome Gene
For additional details, read the articles at the links below: ๐ญ๐ต๐ต๐ต: https://pubmed.ncbi.nlm.nih.gov/10617473/ ๐ฎ๐ฌ๐ฌ๐ฎ: https://pubmed.ncbi.nlm.nih.gov/12442270/ ๐ฎ๐ฌ๐ฌ๐ด: https://pubmed.ncbi.nlm.nih.gov/18178638/
Permanent link to this article: https://inheritedcancer.net/post121820/
ICARE Social Media Post December 2020
CDH1 Cancer Risks
ICARE Social Media Post December 2020
CDH1 Cancer Risks
When a ๐พ๐ฟ๐1 mutation is identified, several factors should be considered to figure out what the cancer risks might be and what medical management should be advised. Specifically, differences in cancer risks among those with a ๐พ๐ฟ๐1 mutation are not well understood. Identifying a ๐พ๐ฟ๐1 mutation in families with hereditary diffuse gastric cancer (HDGC) …
Permanent link to this article: https://inheritedcancer.net/post121520/
ICARE Social Media Post December 2020
PALB2-associated Metastatic Breast Cancer
ICARE Social Media Post December 2020
PALB2-associated Metastatic Breast Cancer
For further information, view the article at: https://ascopubs.org/doi/abs/10.1200/JCO.20.02151
Permanent link to this article: https://inheritedcancer.net/post121120/
ICARE Social Media Post December 2020
New NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Guidelines
ICARE Social Media Post December 2020
New NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Guidelines
The National Comprehensive Cancer Network (NCCN) released new guidelines on November 20th for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/…/physician_gls/pdf/genetics_bop.pdf
Permanent link to this article: https://inheritedcancer.net/post120820/
ICARE Social Media Post December 2020
Broader Germline Testing for Urothelial Cancer
ICARE Social Media Post December 2020
Broader Germline Testing for Urothelial Cancer
The most common inherited form of urothelial cancers is Lynch Syndrome. However, a study showed that of 586 individuals with urothelial cancer, 80 had a mutation in an inherited cancer gene (14%). Mutations in several genes were observed; however, ๐๐๐2 and ๐ฝ๐๐พ๐ผ2 were both significantly associated with urothelial cancer (odds ratio of 3.7). Confirmatory …
Permanent link to this article: https://inheritedcancer.net/post120420/
ICARE Social Media Post December 2020
Breast Cancer Polygenic Risk Score May Help Predict Risk of Contralateral Disease
ICARE Social Media Post December 2020
Breast Cancer Polygenic Risk Score May Help Predict Risk of Contralateral Disease
For further information, view the article available at: https://www.sciencedirect.com/…/pii/S0002929720303219
Permanent link to this article: https://inheritedcancer.net/post120120/
ICARE Social Media Post November 2020
Olaparib May Be Cost-Effective Maintenance Treatment For Women With Newly Diagnosed Ovarian Cancer and BRCA Mutation
ICARE Social Media Post November 2020
Olaparib May Be Cost-Effective Maintenance Treatment For Women With Newly Diagnosed Ovarian Cancer and BRCA Mutation
For further information, view the article available at: https://www.gynecologiconcology-online.net/…/fulltext
Permanent link to this article: https://inheritedcancer.net/post112720/
ICARE Social Media Post November 2020
Impact of Pregnancy After Breast Cancer in Women With Deleterious Germline BRCA Mutations
ICARE Social Media Post November 2020
Impact of Pregnancy After Breast Cancer in Women With Deleterious Germline BRCA Mutations
Check out the original article by visiting: https://pubmed.ncbi.nlm.nih.gov/32673153/
Permanent link to this article: https://inheritedcancer.net/post112420/
ICARE Social Media Post November 2020
ASCO Guideline Updates: Breast Cancer
ICARE Social Media Post November 2020
ASCO Guideline Updates: Breast Cancer
The American Society of Clinical Oncology (ASCO) published updated guidelines for the management of hereditary breast cancer for the following gene carriers: ๐ฝ๐๐พ๐ผ1/2 โข Consider breast-conserving therapy โข Consider nipple-sparing mastectomy, if medically appropriate โข Advanced breast cancer: โซธ PARP inhibitors (olaparib, talazoparib) preferred over non-platinum single agent chemotherapy โซธ Platinum agents are recommended …
Permanent link to this article: https://inheritedcancer.net/post112020/
ICARE Social Media Post November 2020
ASCO Guidelines for Patients with Metastatic Pancreatic Cancer
ICARE Social Media Post November 2020
ASCO Guidelines for Patients with Metastatic Pancreatic Cancer
For additional details, refer to the article available at: https://ascopubs.org/doi/full/10.1200/JCO.20.01364
Permanent link to this article: https://inheritedcancer.net/post111720/
ICARE Social Media Post November 2020
Polygenic Risk Scores in Predicting Breast Cancer Risk
ICARE Social Media Post November 2020
Polygenic Risk Scores in Predicting Breast Cancer Risk
For further information, view the article available at: https://ascopubs.org/doi/full/10.1200/PO.19.00360
Permanent link to this article: https://inheritedcancer.net/post111320/
ICARE Social Media Post November 2020
B-GREAT 2020 Newsletter
ICARE Social Media Post November 2020
B-GREAT 2020 Newsletter
The B-GREAT 2020 Newsletter is now available! Check out this latest edition for research updates and information about racial inequalities in healthcare. You can read the newsletter by visiting: https://bgreatinitiative.inheritedcancer.net/wp-content/uploads/BGREAT-Newsletter-2020.pdf. Please feel free to share with family members, friends, and/or your healthcare providers. We will be publishing these newsletters twice a year starting in 2021. …
Permanent link to this article: https://inheritedcancer.net/post111020/
ICARE Social Media Post November 2020
Clinical Trial Participation Powers Patient’s Positive Attitude
ICARE Social Media Post November 2020
Clinical Trial Participation Powers Patient’s Positive Attitude
Brooke Thomas has leaned on 12 years of experience as a medical social worker and found ways to stay positive and upbeat through it all – and she has a lot to be positive about these days, thanks to an amazing response to her treatment as part of a clinical trial at Vanderbilt-Ingram Cancer Center. …
Permanent link to this article: https://inheritedcancer.net/post110620/
ICARE Social Media Post November 2020
Identifying Individuals At-Risk for Inherited Cancer: Disparities Among Ovarian Cancer Patients
ICARE Social Media Post November 2020
Identifying Individuals At-Risk for Inherited Cancer: Disparities Among Ovarian Cancer Patients
This study highlights disparities among ovarian cancer patients. For further information, view the article at: https://pubmed.ncbi.nlm.nih.gov/30964716/
Permanent link to this article: https://inheritedcancer.net/post110320/
ICARE Social Media Post October 2020
CDH1: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
CDH1: Cancer Risks and Risk Management
Gene: ๐พ๐ฟ๐๐ญ Cancer Risks and Management per NCCN Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021 and Gastric Version 3.2020: ๐ช๐ผ๐บ๐ฒ๐ป: Breast cancer risk: Elevated at 55% – Recommend annual mammogram starting at age 30; consider breast MRI with contrast starting at age 30. ๐ ๐ฒ๐ป ๐ฎ๐ป๐ฑ ๐ช๐ผ๐บ๐ฒ๐ป: Stomach cancer risk: Elevated at 83% for women, and 67% …
Permanent link to this article: https://inheritedcancer.net/post103020/
ICARE Social Media Post October 2020
Polygenic Risk Scores in Refining Breast Cancer Risks
ICARE Social Media Post October 2020
Polygenic Risk Scores in Refining Breast Cancer Risks
For further information, view the article available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767768
Permanent link to this article: https://inheritedcancer.net/post102720/
ICARE Social Media Post October 2020
PTEN: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
PTEN: Cancer Risks and Risk Management
Gene: ๐๐๐๐ Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021: ๐ช๐ผ๐บ๐ฒ๐ป: Breast cancer risk: Elevated at 85% – Recommend annual mammogram starting at age 30-35 (or 5-10 years before the earliest known breast cancer in the family); consider breast MRI with contrast starting at age 30-35; consider …
Permanent link to this article: https://inheritedcancer.net/post102320/
ICARE Social Media Post October 2020
Three Genetic Variants Identified That May Raise Breast Cancer Risks in Men
ICARE Social Media Post October 2020
Three Genetic Variants Identified That May Raise Breast Cancer Risks in Men
For more information, view the article available at: https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaa101/5885091
Permanent link to this article: https://inheritedcancer.net/post102020/
ICARE Social Media Post October 2020
TP53: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
TP53: Cancer Risks and Risk Management
Gene: ๐๐๐ฑ๐ฏ Syndrome: Li-Fraumeni Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021: ๐ช๐ผ๐บ๐ฒ๐ป: Breast cancer risk: Elevated at 54% – Recommend clinical breast exam every 6-12 months starting at age 20, annual breast MRI with contrast starting at age 20, and annual mammogram starting at age 30; …
Permanent link to this article: https://inheritedcancer.net/post101620/
ICARE Social Media Post October 2020
New ASCO Guidelines On Use Of PARP Inhibitors To Manage Ovarian Cancer
ICARE Social Media Post October 2020
New ASCO Guidelines On Use Of PARP Inhibitors To Manage Ovarian Cancer
New guidelines for the use of PARP inhibitors to treat ovarian cancer among those with BRCA1 or BRCA2 mutations were published through the American Society of Clinical Oncology (ASCO) to guide providers about the role of this class of drugs in the management of this type of cancer. Link to the guidelines are available at: …
Permanent link to this article: https://inheritedcancer.net/post101320/
ICARE Social Media Post October 2020
CHEK2: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
CHEK2: Cancer Risks and Risk Management
Gene: ๐พ๐๐๐2 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 & Breast/Ovarian/Pancreatic Version 1.2021: ๐ช๐ผ๐บ๐ฒ๐ป: Breast Cancer Risk: Elevated at 28-44% – Recommend annual mammogram starting at age 40 and consider annual breast MRIs with contrast starting at age 40. ๐ ๐ฒ๐ป ๐ฎ๐ป๐ฑ ๐ช๐ผ๐บ๐ฒ๐ป: Colorectal Cancer Risk: Elevated …
Permanent link to this article: https://inheritedcancer.net/post100920/
ICARE Social Media Post October 2020
Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer
ICARE Social Media Post October 2020
Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer
Among BRCA carriers with metastatic breast cancer, the combination of veliparib AND chemotherapy with platinum-based agents (carboplatin) and taxanes (paclitaxel) led to a longer duration of progression free survival (disease that did not progress), compared to those treated with ONLY chemotherapy. To read the full article visit: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30447-2/fulltext [This finding was previously outlined last year …
Permanent link to this article: https://inheritedcancer.net/post100620/
ICARE Social Media Post October 2020
ATM: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
ATM: Cancer Risks and Risk Management
Gene: ๐ผ๐๐ Cancer Risks and Management (per NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2021) ๐ช๐ผ๐บ๐ฒ๐ป: Breast cancer risk: Elevated at 30% – Recommend annual mammogram starting at age 40 and consider annual breast MRIs starting at age 40. Ovarian cancer risk: Possibly increased, not well established – Manage based on family history. …
Permanent link to this article: https://inheritedcancer.net/post100220/
ICARE Social Media Post September 2020
Living with Lynch 2020 Virtual Patient Workshop
ICARE Social Media Post September 2020
Living with Lynch 2020 Virtual Patient Workshop
SJoin the Colon Cancer Coalition and AliveAndKickn for the Living with Lynch 2020 Virtual Patient Workshop on๐๐ฟ๐ถ๐ฑ๐ฎ๐, ๐ข๐ฐ๐๐ผ๐ฏ๐ฒ๐ฟ ๐ต๐๐ต ๐ณ๐ฟ๐ผ๐บ ๐ญ๐ฝ๐บ-๐ฑ๐ฝ๐บ ๐๐ง to hear unique patient perspectives and the latest information from experts on Lynch syndrome. Visit https://www.livingwithlynch.org/2020-living-with-lynch to register for this free workshop today!
Permanent link to this article: https://inheritedcancer.net/post92920/
ICARE Social Media Post September 2020
AACR Cancer Disparities Progress Report 2020
ICARE Social Media Post September 2020
AACR Cancer Disparities Progress Report 2020
The American Association for Cancer Research (AACR) published a Cancer Disparities Progress Report. “… our limited knowledge of cancer biology in racial and ethnic minorities, including their inherited cancer predisposition and the genomic underpinnings of cancer initiation and progression, diminishes the potential of precision medicine in these populations.” This report discusses relevant information about inherited …
Permanent link to this article: https://inheritedcancer.net/post92520/
ICARE Social Media Post September 2020
FDA Grants Breakthrough Therapy Status to MK-6482 for Treatment of Patients With VHL Disease-Associated Renal Cell Carcinoma
ICARE Social Media Post September 2020
FDA Grants Breakthrough Therapy Status to MK-6482 for Treatment of Patients With VHL Disease-Associated Renal Cell Carcinoma
For additional information, please visit: https://www.onclive.com/view/fda-grants-breakthrough-status-to-mk-6482-for-select-vhl-disease-associated-rcc Also check out the abstract presented at the 2020 ASCO meeting: https://meetinglibrary.asco.org/record/185945/abstract
Permanent link to this article: https://inheritedcancer.net/post92220/
ICARE Social Media Post September 2020
Rucaparib May Have Antitumor Activity in Male BRCA Carriers with Metastatic Prostate Cancer
ICARE Social Media Post September 2020
Rucaparib May Have Antitumor Activity in Male BRCA Carriers with Metastatic Prostate Cancer
For further information, view the article available at: https://ascopubs.org/doi/full/10.1200/JCO.20.01035
Permanent link to this article: https://inheritedcancer.net/post91820/
ICARE Social Media Post September 2020
ICARE Summer 2020 Newsletter
ICARE Social Media Post September 2020
ICARE Summer 2020 Newsletter
The ICARE Summer 2020 Newsletter is now available! Check out this latest edition for recent research and clinical updates as well as a Q&A with a nationally renowned clinical geneticist from Vanderbilt-Ingram Cancer Center. You can read the newsletter by visiting: https://inheritedcancer.net/wp-content/uploads/ICARE-2020-Summer-Newsletter.pdf Please feel free to share with family members, friends, and/or your …
Permanent link to this article: https://inheritedcancer.net/post91620/
ICARE Social Media Post September 2020
NCCN Genetic Testing Criteria Updates by Cancer
ICARE Social Media Post September 2020
NCCN Genetic Testing Criteria Updates by Cancer
The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to genetic testing criteria by cancer type as follows: Breast Cancer: Broadened to include relatives with ALL grades of prostate cancer (not just high-grade) Now having multiple breast cancer diagnoses is NOT dependent on whether the diagnoses were …
Permanent link to this article: https://inheritedcancer.net/post91520/
ICARE Social Media Post September 2020
NCCN Breast Cancer Pathology Updates
ICARE Social Media Post September 2020
NCCN Breast Cancer Pathology Updates
The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020. Check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
Permanent link to this article: https://inheritedcancer.net/post91420/
ICARE Social Media Post September 2020
NCCN Genetic Testing Choice Updates
ICARE Social Media Post September 2020
NCCN Genetic Testing Choice Updates
The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to genetic testing choices and considerations as follows: Choice of multi-gene panel may be guided by genes included, analyses offered, and financial assistance programs available for family testing Significant limitations in interpretations of polygenic risk scores: NOT recommended for …
Permanent link to this article: https://inheritedcancer.net/post91120/
ICARE Social Media Post September 2020
NCCN Breast Cancer Risk Management Updates by Gene
ICARE Social Media Post September 2020
NCCN Breast Cancer Risk Management Updates by Gene
The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to breast cancer risk management recommendations by gene as follows: NBN – high-risk breast screening was removed as there is insufficient evidence to support high cancer risks BARD1 – added consideration for high-risk breast screening starting at age 40 …
Permanent link to this article: https://inheritedcancer.net/post91020/
ICARE Social Media Post September 2020
ACMG Guidelines for Genetic Testing for All Breast Cancer
ICARE Social Media Post September 2020
ACMG Guidelines for Genetic Testing for All Breast Cancer
Check out Vanderbilt’s article about genetic testing considerations at: https://discover.vumc.org/2020/02/genetic-testing-considerations-for-breast-cancer-patients/ Check out the original document from the American College of Medical Genetics and Genomics at: https://www.nature.com/articles/s41436-019-0712-x
Permanent link to this article: https://inheritedcancer.net/post90820/
ICARE Social Media Post September 2020
GREM1 Duplication
ICARE Social Media Post September 2020
GREM1 Duplication
The GREM1 gene leads to hereditary mixed polyposis syndrome, characterized by multiple polyps of mixed pathology and high risks for colorectal cancer. A specific duplication in the 5′ regulatory region of the GREM1 gene has been found in a subset of Ashkenazi Jewish individuals with hereditary mixed polyposis syndrome; therefore, GREM1 genetic testing is …
Permanent link to this article: https://inheritedcancer.net/post90420/
ICARE Social Media Post September 2020
Biallelic Mutations in BRCA1 Cause Fanconi Anemia
ICARE Social Media Post September 2020
Biallelic Mutations in BRCA1 Cause Fanconi Anemia
BRCA1 is not typically thought to be one of the genes which cause Fanconi anemia. However, rare cases of individuals with biallelic BRCA1 mutations (mutations in both copies of the gene) have been reported. One case involved a woman who had breast cancer at age 23, and was born with multiple birth defects consistent with …
Permanent link to this article: https://inheritedcancer.net/post90120/
ICARE Social Media Post August 2020
Older Women with Breast Cancer Have Higher Risks of Ovarian and Other Cancers
ICARE Social Media Post August 2020
Older Women with Breast Cancer Have Higher Risks of Ovarian and Other Cancers
Among 4,500 post-menopausal women with breast cancer, 3.55% had a mutation in a gene associated with inherited breast cancer (3-fold higher than what was seen among women who were cancer-free). BRCA1/2 mutations were seen more frequently in women diagnosed with breast cancer at or below age 65 (2.21%) compared to those diagnosed after age 65 …
Permanent link to this article: https://inheritedcancer.net/post82820/
ICARE Social Media Post August 2020
Pheochromocytoma and Paraganglioma Genetic Testing
ICARE Social Media Post August 2020
Pheochromocytoma and Paraganglioma Genetic Testing
More than 40% of patients with pheochromocytoma or paraganglioma, regardless of age and family history, carry an inherited gene mutation. Given that gene mutation carriers may benefit from gene-specific cancer screening, all individuals diagnosed with one of these tumors should seek genetic counseling to discuss genetic testing options. Genes that predispose to pheochromocytoma and paraganglioma …
Permanent link to this article: https://inheritedcancer.net/post82520/
ICARE Social Media Post August 2020
Optimal Timing of Prophylactic Gastrectomy for CDH1 Carriers
ICARE Social Media Post August 2020
Optimal Timing of Prophylactic Gastrectomy for CDH1 Carriers
Individuals with a CDH1 mutation and classic personal and family history of diffuse gastric (stomach) cancer have a very high risk of developing and dying from stomach cancer, if they do not have preventive surgery to remove their stomach. A simulation study to assess prophylactic total gastrectomy (PTG; the removal of the stomach to prevent …
Permanent link to this article: https://inheritedcancer.net/post82120/
ICARE Social Media Post August 2020
MRI Surveillance Has Very Low Yield After Bilateral Mastectomy and Reconstruction
ICARE Social Media Post August 2020
MRI Surveillance Has Very Low Yield After Bilateral Mastectomy and Reconstruction
A study of 159 women, including BRCA carriers, who had bilateral mastectomy with reconstruction, underwent breast MRI screening. The results showed few women had detection of breast cancer through MRI, after their bilateral mastectomy. These results support the recommendation against screening MRI in women who have had bilateral mastectomy with reconstruction due to a diagnosis …
Permanent link to this article: https://inheritedcancer.net/post81820/
ICARE Newsletter Summer 2020
Treatment Advances Among Those with Neurofibromatosis Type 1
ICARE Newsletter Summer 2020
Treatment Advances Among Those with Neurofibromatosis Type 1
There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Neurofibromatosis Type 1 (NF1): The FDA granted selumetinib (a MEK inhibitor) breakthrough therapy designation for treatment of inoperable plexiform neurofibromas.
Permanent link to this article: https://inheritedcancer.net/8nls2020/
ICARE Newsletter Summer 2020
Treatment Advances Among Those with Lynch Syndrome
ICARE Newsletter Summer 2020
Treatment Advances Among Those with Lynch Syndrome
There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Lynch Syndrome: Colorectal Cancer: Among patients with MSI-H or MMR-deficient colorectal cancers (frequently seen among those with Lynch syndrome), pembrolizumab …
Permanent link to this article: https://inheritedcancer.net/7nls2020/
ICARE Newsletter Summer 2020
Ask the Expert
ICARE Newsletter Summer 2020
Ask the Expert
In each newsletter, we give participants the opportunity to have their questions addressed by experts in the field. This question was addressed by Georgia Wiesner, MD, MS, a nationally renowned clinical cancer geneticist, who is an Ingram Professor of Cancer Research, Professor of Medicine in the Division of Genetic Medicine, and the Director of the …
Permanent link to this article: https://inheritedcancer.net/6nls2020/
ICARE Newsletter Summer 2020
Identifying Individuals At-Risk for Inherited Cancer
ICARE Newsletter Summer 2020
Identifying Individuals At-Risk for Inherited Cancer
We have known for a while that many people who have mutations in BRCA1/2 and other inherited cancer risk genes are unaware of their mutation as they have not yet had genetic testing. A recent study among women aged 20 or older living in California and Georgia, which included almost 80,000 breast cancer patients and …
Permanent link to this article: https://inheritedcancer.net/4nls2020/
ICARE Newsletter Summer 2020
Community Spotlight
ICARE Newsletter Summer 2020
Community Spotlight
PTEN is one of the bodyโs tumor suppressor genes, which controls cell growth. When a PTEN mutation is present, cells may grow uncontrollably, causing tumors to develop that may become cancerous. A patient born with a PTEN mutation is at high risk for developing breast, thyroid, kidney, colon, and endometrial cancer. My PTEN journey began …
Permanent link to this article: https://inheritedcancer.net/spotlightnls2020/
ICARE Newsletter Summer 2020
Treatment Advances Among Those with Von-Hippel Lindau (VHL) Disease
ICARE Newsletter Summer 2020
Treatment Advances Among Those with Von-Hippel Lindau (VHL) Disease
There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Von-Hippel Lindau (VHL) Disease: Among patients with VHL-associated clear cell renal cell carcinoma (RCC), a recent study suggested potential benefit …
Permanent link to this article: https://inheritedcancer.net/9nls2020/
ICARE Newsletter Summer 2020
Treatment Advances Among BRCA1/2 Carriers
ICARE Newsletter Summer 2020
Treatment Advances Among BRCA1/2 Carriers
There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: BRCA1/2 Carriers: Breast Cancer: For those with later stage or metastatic breast cancer, the FDA currently has approvals for the use …
Permanent link to this article: https://inheritedcancer.net/2nls2020/
ICARE Newsletter Summer 2020
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines
ICARE Newsletter Summer 2020
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines (Version 1.2020, posted July 21, 2020) For individuals with Lynch Syndrome: Cancer risks were updated based on information from recent studies: Main updates included cancer risks in PMS2 (endometrial, ovarian, and prostate cancer), MSH2 and EPCAM (prostate and brain cancer), and MSH6 (prostate …
Permanent link to this article: https://inheritedcancer.net/1nls2020/
ICARE Newsletter Summer 2020
Guideline-Concordant Care Among Women with Inherited Cancer Gene Mutations
ICARE Newsletter Summer 2020
Guideline-Concordant Care Among Women with Inherited Cancer Gene Mutations
Testing for inherited cancer among breast cancer patients has tremendous potential to guide appropriate care following testing. Yet, a number of efforts suggest that women are not consistently receiving care according to current national guidelines based on their genetic test result. In fact, results from studies suggest many women for whom risk-reducing mastectomy would not …
Permanent link to this article: https://inheritedcancer.net/3nls2020/
ICARE Newsletter Summer 2020
Polygenic Risk Scores and Colon Cancer
ICARE Newsletter Summer 2020
Polygenic Risk Scores and Colon Cancer
A recent study focused on how polygenic risk scores (PRS) may be related to colorectal cancers. Of note, PRS are calculated using genetic differences throughout someoneโs DNA, in combination with their clinical and family history of cancer. PRS, alongside environmental and lifestyle risk factors, may help to identify people who may benefit from screening at …
Permanent link to this article: https://inheritedcancer.net/5nls2020/
ICARE Social Media Post August 2020
Inherited Prostate Cancer Risk
ICARE Social Media Post August 2020
Inherited Prostate Cancer Risk
Over 600,000 men age 40 and older who were part of a family with at least three consecutive generations affected with prostate cancer were studied from the Utah Population Database. Findings from this study showed that: 36,000 had prostate cancer (5.9%) 2,500 had early-onset disease (7%) 4,000 had lethal disease (11.1%) 15,000 had clinically significant …
Permanent link to this article: https://inheritedcancer.net/post81420/
ICARE Social Media Post August 2020
CDC Resource for Free Breast Cancer Screening
ICARE Social Media Post August 2020
CDC Resource for Free Breast Cancer Screening
We are here to help! Our followers asked us to provide information about screening resources for women with hereditary breast cancer. We would like to make folks aware about a CDC program that provides free breast cancer screening for women who are uninsured and underinsured. โฃโฃ โฃโฃ Check out more information at: https://www.cdc.gov/cancer/nbccedp/ โฃโฃ
Permanent link to this article: https://inheritedcancer.net/post81120/
ICARE Social Media Post August 2020
Presymptomatic BRCA1/2 Carriers May Have Better Outcomes
ICARE Social Media Post August 2020
Presymptomatic BRCA1/2 Carriers May Have Better Outcomes
Check out the article at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2768011
Permanent link to this article: https://inheritedcancer.net/post80720/
ICARE Social Media Post August 2020
Disparities in BRCA Counseling Across Diverse Populations
ICARE Social Media Post August 2020
Disparities in BRCA Counseling Across Diverse Populations
A recently published study based on data from our participants showed that few young Black women with breast cancer see a genetic counselor AND those with insurance are LESS likely to see a genetic counselor. โฃโฃ โฃโฃ For more information, check out the full study at: https://www.nature.com/articles/s41436-020-0762-0
Permanent link to this article: https://inheritedcancer.net/post80420/
ICARE Social Media Post August 2020
Genes That Predispose African American Women to Breast Cancer
ICARE Social Media Post August 2020
Genes That Predispose African American Women to Breast Cancer
A recently published study based on data including our participants identified genes that predispose African American patients to breast cancer. For more information, check out the full study at: https://academic.oup.com/jnci/article/doi/10.1093/jnci/djaa040/5838706.
Permanent link to this article: https://inheritedcancer.net/post80320/
ICARE Social Media Post July 2020
Cancer Risks in Men with BRCA1 and BRCA2 Pathogenic Variants
ICARE Social Media Post July 2020
Cancer Risks in Men with BRCA1 and BRCA2 Pathogenic Variants
Check out the article at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2767423
Permanent link to this article: https://inheritedcancer.net/post73120/
ICARE Social Media Post July 2020
Updates to 2020 NCCN Genetic/Familial Colorectal Guidelines
ICARE Social Media Post July 2020
Updates to 2020 NCCN Genetic/Familial Colorectal Guidelines
The National Comprehensive Cancer Network (NCCN) released new guidelines for 2020 on July 21, 2020. The big changes included refining some of the risks for genes involved in Lynch Syndrome, and providing specific guidance about cancer screening that may slightly differ by gene. You can check out the full guidelines by creating a FREE account …
Permanent link to this article: https://inheritedcancer.net/post72420/
ICARE Social Media Post July 2020
Racial Inequalities in Genetics
ICARE Social Media Post July 2020
Racial Inequalities in Genetics
[ngg src=”galleries” ids=”1″ display=”basic_slideshow” arrows=”1″ show_thumbnail_link=”0″]It is important to talk about racial inequalities in healthcare as it affects the care received among Black patients. Through our research efforts, we not only want to address the issue of racism but also think about ways to make healthcare more equitable. A recently published study including our research …
Permanent link to this article: https://inheritedcancer.net/post72120/
ICARE Social Media Post July 2020
Breast Cancer Risks May be Higher in Women with Two CHEK2 Mutations Versus One CHEK2 Mutation
ICARE Social Media Post July 2020
Breast Cancer Risks May be Higher in Women with Two CHEK2 Mutations Versus One CHEK2 Mutation
A study comparing women with two CHEK2 mutations to one CHEK2 mutation showed that those with two mutations were: -more likely to get breast cancer (80.6% versus 41.2%) -more likely to be diagnosed at or below age 50 (61.3% versus 23.9%) -more likely to have a second breast cancer diagnosis (22.6% versus 8.1%) These findings …
Permanent link to this article: https://inheritedcancer.net/post71720/
ICARE Social Media Post July 2020
Individuals with a First-Degree Relative with Blood Cancer Are at Increased Risk for Blood-Related Cancer
ICARE Social Media Post July 2020
Individuals with a First-Degree Relative with Blood Cancer Are at Increased Risk for Blood-Related Cancer
Individuals with a first-degree relative (for example, parent, sibling, or child) with blood cancer, such as lymphoma, have a higher chance of being diagnosed with blood-related cancer (i.e., hematologic malignancy), according to a recent study. The risk to develop certain blood cancers depends on how closely related the relative is (e.g., higher risks for first-degree …
Permanent link to this article: https://inheritedcancer.net/post71420/
ICARE Social Media Post July 2020
BRCA1/2 and Other Gene Carriers with Breast Cancer Donโt Always Receive Recommended Treatment
ICARE Social Media Post July 2020
BRCA1/2 and Other Gene Carriers with Breast Cancer Donโt Always Receive Recommended Treatment
BRCA1/2 and other gene mutation carriers with early stage breast cancer are not always receiving cancer treatment as recommended by national guidelines. Even though more and more people have been tested for hereditary cancer over the years, using this information accurately to guide treatment has not been as successful. These findings highlight the need for …
Permanent link to this article: https://inheritedcancer.net/post71020/
ICARE Social Media Post July 2020
Pancreatic Cancer Can Run in Families
ICARE Social Media Post July 2020
Pancreatic Cancer Can Run in Families
Individuals with a family history of pancreatic cancer have a higher risk to develop pancreatic cancer. A recent study reported the following pancreatic cancer risks compared to the general population, based on relationship to an individual with pancreatic cancer: First-degree relative (e.g., parent, sibling, child) โ 1.76 fold higher Second-degree relative (e.g., aunts, uncles, grandparents) …
Permanent link to this article: https://inheritedcancer.net/post70720/
ICARE Social Media Post July 2020
Community Spotlight: Mari-Lynn Slayton
ICARE Social Media Post July 2020
Community Spotlight: Mari-Lynn Slayton
In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our community spotlight in our Winter 2016 ICARE Newsletter is Mari-Lynn Slayton, who was found to have a PALB2 mutation after two breast cancer diagnoses. Check out her story at: https://inheritedcancer.net/community-spotlight/
Permanent link to this article: https://inheritedcancer.net/post70220/
ICARE Social Media Post June 2020
Advances in Treatment for Colorectal Cancer
ICARE Social Media Post June 2020
Advances in Treatment for Colorectal Cancer
On June 29, 2020, the FDA approved the use of Keytruda (pembrolizumab), as first-line treatment in unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer. Among people with Lynch syndrome, the risk for colorectal cancer (which often has microsatellite instability and/or mismatch-repair deficiency) is raised. Keytruda (pembrolizumab) showed to double the progression-free …
Permanent link to this article: https://inheritedcancer.net/post63020/
ICARE Social Media Post June 2020
Higher Chance of VUS Results in Minorities
ICARE Social Media Post June 2020
Higher Chance of VUS Results in Minorities
Asian, Hispanic, and Black women with breast cancer had higher rates of variants of uncertain significance (VUS) on genetic test results for hereditary cancer genes compared to White women with breast cancer according to a recent study. Check out the full article at https://link.springer.com/article/10.1007%2Fs13187-019-01646-8
Permanent link to this article: https://inheritedcancer.net/post62620/
ICARE Social Media Post June 2020
Community Spotlight: Kelly Frank
ICARE Social Media Post June 2020
Community Spotlight: Kelly Frank
June is cancer survivor month! In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our community spotlight in our Winter 2019 ICARE Newsletter is Kelly Frank, who was found to have a BRIP1 mutation after an ovarian cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/
Permanent link to this article: https://inheritedcancer.net/post62320/
ICARE Social Media Post June 2020
Advances in Treatment for BRCA-Mutated Triple Negative Breast Cancer
ICARE Social Media Post June 2020
Advances in Treatment for BRCA-Mutated Triple Negative Breast Cancer
In a study of 914 women with different breast cancer subtypes, overall pathologic complete response rates were: Higher in those with BRCA1/2 mutations (60.4% versus 46.7%) No differences were seen in those with mutations in other inherited cancer genes Among patients with triple-negative breast cancer, BRCA1/2 mutations had highest response rates to treatment in both …
Permanent link to this article: https://inheritedcancer.net/post61920/
ICARE Social Media Post June 2020
Community Spotlight: Patricia Blumenthal
ICARE Social Media Post June 2020
Community Spotlight: Patricia Blumenthal
In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our community spotlight in our Summer 2018 ICARE Newsletter is Patricia Blumenthal, who was found to have a BRCA2 mutation. Check out her story at: https://inheritedcancer.net/community-spotlight/
Permanent link to this article: https://inheritedcancer.net/post61620/
ICARE Social Media Post June 2020
Advances in BRCA1/2 Breast Cancer Treatment
ICARE Social Media Post June 2020
Advances in BRCA1/2 Breast Cancer Treatment
Through a randomized phase 2 study (called the INFORM trial) among BRCA1/2 carriers with breast cancer, cisplatin was no better in inducing pathologic complete remission compared to AC. The pathologic complete remission rate was 18% for cisplatin and 26% for AC. Cisplatin is not better than other chemotherapy for induction therapy for breast cancers in …
Permanent link to this article: https://inheritedcancer.net/post61220/
ICARE Social Media Post June 2020
Community Spotlight: Christy Mattey
ICARE Social Media Post June 2020
Community Spotlight: Christy Mattey
In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our latest community spotlight in our Winter 2017 ICARE Newsletter is Christy Mattey, who was found to have a CHEK2 mutation after a breast cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/
Permanent link to this article: https://inheritedcancer.net/post60920/
ICARE Social Media Post June 2020
Advances in Treatment for Pancreatic Cancer: Cisplatin + Gemcitabine
ICARE Social Media Post June 2020
Advances in Treatment for Pancreatic Cancer: Cisplatin + Gemcitabine
In BRCA1/2 or PALB2 carriers with stage 3 or 4 pancreatic cancer, the combination of cisplatin + gemtricitabine with veliparib (a PARP inhibitor), did NOT seem to provide additional benefit over cisplatin + gemtricitabine alone. Through this phase 2 randomized control trial, response rates in both treatment arms were high with similar overall survival rates. …
Permanent link to this article: https://inheritedcancer.net/post60520/
ICARE Social Media Post June 2020
Community Spotlight: Terry Arnold
ICARE Social Media Post June 2020
Community Spotlight: Terry Arnold
June is Cancer Survivor Month! In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our latest community spotlight in our Summer 2017 ICARE Newsletter is Terry Arnold, who was found to have a BRCA1 mutation after a breast cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/
Permanent link to this article: https://inheritedcancer.net/post60220/
ICARE Social Media Post May 2020
Platinum Based Chemotherapy for Metastatic Pancreatic Cancer
ICARE Social Media Post May 2020
Platinum Based Chemotherapy for Metastatic Pancreatic Cancer
A recent study found that patients with metastatic pancreatic cancer who had mutations in the DNA repair genes (either inherited or just in the tumor) had better clinical outcomes after platinum-based chemotherapy compared to patients without these mutations. Check out the link to full article: https://clincancerres.aacrjournals.org/content/early/2020/05/20/1078-0432.CCR-20-0418
Permanent link to this article: https://inheritedcancer.net/post52920/
ICARE Social Media Post May 2020
Cancer Risk Management Among Female BRCA1/2, PALB2, CHEK2, and ATM Carriers in ICARE
ICARE Social Media Post May 2020
Cancer Risk Management Among Female BRCA1/2, PALB2, CHEK2, and ATM Carriers in ICARE
A new article was recently published based on data from BRCA1/2, PALB2, CHEK2, and ATM carriers in ICARE. Findings suggest potential overtreatment through risk-reducing surgery among women with pathogenic/likely pathogenic variants in breast cancer genes. This highlights the importance of promoting guideline-adherent, risk-appropriate care. Check out the full article at https://rdcu.be/b4mbg
Permanent link to this article: https://inheritedcancer.net/post52620/
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Olaparib
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Olaparib
On May 19, 2020 the FDA approved the use of olaparib (Lynparza) as treatment in BRCA and other gene carriers (homologous recombination repair genes) with metastatic castration-resistant prostate cancer who have been treated with enzalutamide or abiraterone. Link to full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer
Permanent link to this article: https://inheritedcancer.net/post52220/
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Rucaparib
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Rucaparib
On May 15, 2020 the FDA approved the use of rucaparib (Rubraca) as treatment in BRCA carriers with metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Link to full article: https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate
Permanent link to this article: https://inheritedcancer.net/post51920/
ICARE Social Media Post May 2020
MRI May Detect Breast Cancer Earlier than Mammograms
ICARE Social Media Post May 2020
MRI May Detect Breast Cancer Earlier than Mammograms
The National Comprehensive Cancer Network (NCCN) currently recommends an annual breast MRI and an annual mammography for high-risk women (lifetime breast cancer risk at or above 20%). Among women at high risk for breast cancer, MRI detected breast cancer at an earlier stage than mammograms. Women with BRCA1/2 and TP53 were NOT included in this …
Permanent link to this article: https://inheritedcancer.net/post51520/
ICARE Social Media Post May 2020
Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib & bevacizumab
ICARE Social Media Post May 2020
Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib & bevacizumab
On May 8, 2020 the FDA approved the use of olaparib (Lynparza) as first-line maintenance treatment in BRCA1/2 carriers (deleterious or suspected deleterious mutations) and/or a genomic instability, with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Link to full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary
Permanent link to this article: https://inheritedcancer.net/post51220/
ICARE Social Media Post May 2020
Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib
ICARE Social Media Post May 2020
Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib
In recognition of World Ovarian Cancer Day, we’d like to share some exciting results from a study of women with ovarian cancer and a BRCA mutation: In a recent phase III trial, olaparib (PARP inhibitor) showed improved response and progression-free survival compared with chemotherapy (without platinum) in BRCA carriers with platinum-sensitive relapsed ovarian cancer who …
Permanent link to this article: https://inheritedcancer.net/post50820/
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Olaparib
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Olaparib
Findings from a recent study showed that olaparib (PARP inhibitor) significantly improved progression-free survival in patients with BRCA1, BRCA2, or ATM genetic alterations. Benefits were also more broadly seen among patients with homologous recombination repair gene defects. Link to full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1911440 Check out the ASCO post article at: https://www.ascopost.com/news/may-2020/olaparib-for-patients-with-mcrpc-and-homologous-recombination-repair-gene-alterations/
Permanent link to this article: https://inheritedcancer.net/post50620/
ICARE Social Media Post May 2020
CDH1: Gastric and Breast Cancer Risks
ICARE Social Media Post May 2020
CDH1: Gastric and Breast Cancer Risks
CDH1 mutation carriers are at higher risk for diffuse gastric cancer (men and women) and lobular breast cancer (women). Current strategies to manage high risks of gastric cancer include prophylactic gastrectomy (i.e., removal of the stomach), which can have severe physical and psychological implications. A recent study found that men have a higher risk of …
Permanent link to this article: https://inheritedcancer.net/post50520/
ICARE Social Media Post May 2020
New Blood Test May Find Ovarian Cancer Early
ICARE Social Media Post May 2020
New Blood Test May Find Ovarian Cancer Early
A study of 80 women identified 4 proteins in blood that may help to detect ovarian cancer early. Further research is still needed with larger groups of women to determine if this new blood test would be a reliable test to find ovarian cancer early. Check out the full article at https://www.nature.com/articles/s41416-019-0544-0
Permanent link to this article: https://inheritedcancer.net/post50120/
ICARE Social Media Post April 2020
Advances in Treatment for Ovarian Cancer in BRCA1/2 Carriers: Niraparib
ICARE Social Media Post April 2020
Advances in Treatment for Ovarian Cancer in BRCA1/2 Carriers: Niraparib
On April 29, 2020 the FDA approved the use of niraparib (Zeluja) as first-line maintenance treatment in BRCA1/2 carriers with advanced ovarian cancer! More details available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
Permanent link to this article: https://inheritedcancer.net/post42920/
ICARE Social Media Post April 2020
PALB2: Cancer Risks and Risk Management
ICARE Social Media Post April 2020
PALB2: Cancer Risks and Risk Management
Gene: PALB2 Cancer Risks and Management (per NCCN version 1.2020): Women: Breast cancer risk: Elevated at 53% – Recommend annual breast MRI with contrast starting at age 30, and annual mammogram with consideration of tomosynthesis starting at age 30; Consider risk-reducing mastectomy. Ovarian cancer risk: Elevated at 5% – Manage based on family history. Men …
Permanent link to this article: https://inheritedcancer.net/post42820/
ICARE Social Media Post April 2020
BRCA2: Cancer Risks and Risk Management
ICARE Social Media Post April 2020
BRCA2: Cancer Risks and Risk Management
Gene: BRCA2 Cancer Risks and Management (per NCCN version 3.2019): Women: Breast cancer risk: Elevated at 60%-70% – Recommend clinical breast exam every 6-12 months starting at age 25, annual breast MRI with contrast starting at age 25, and annual mammogram with consideration of tomosynthesis starting at age 30; consider risk-reducing mastectomy. Ovarian cancer risk: …
Permanent link to this article: https://inheritedcancer.net/post42120/
ICARE Social Media Post April 2020
ASCO Guideline: Genetic Testing for Ovarian Cancer
ICARE Social Media Post April 2020
ASCO Guideline: Genetic Testing for Ovarian Cancer
The American Society of Clinical Oncology (ASCO) recently published a guideline reinforcing the longstanding recommendation that all women diagnosed with epithelial ovarian cancer (EOC) be offered genetic testing for hereditary ovarian cancer genes. Many of these women (>15%) have an inherited mutation, most commonly BRCA1 or BRCA2. Identifying BRCA1/2 mutations may help guide cancer treatment. …
Permanent link to this article: https://inheritedcancer.net/post41720/
ICARE Social Media Post April 2020
BRCA1: Cancer Risks and Risk Management
ICARE Social Media Post April 2020
BRCA1: Cancer Risks and Risk Management
Gene: BRCA1 Cancer Risks and Management (per NCCN version 3.2019): Women: Breast cancer risk: Elevated at 60%-70% – Recommend clinical breast exam every 6-12 months starting at age 25, annual breast MRI with contrast starting at age 25, and annual mammogram with consideration of tomosynthesis starting at age 30; consider risk-reducing mastectomy. Ovarian cancer risk: …
Permanent link to this article: https://inheritedcancer.net/post41420/
ICARE Social Media Post April 2020
Treatment Patterns in Women with Inherited Breast Cancer
ICARE Social Media Post April 2020
Treatment Patterns in Women with Inherited Breast Cancer
Results from a population-based study of over 20,000 women from SEER registries of Georgia and California diagnosed with stage 0 to stage III breast cancer between 2014 and 2016 tested for inherited breast cancer were recently published. Findings suggest that women who test positive for certain mutations receive certain patterns of treatment. These patterns of …
Permanent link to this article: https://inheritedcancer.net/post41020/
ICARE Social Media Post April 2020
EPCAM: Cancer Risks and Risk Management
ICARE Social Media Post April 2020
EPCAM: Cancer Risks and Risk Management
Gene: EPCAM Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 21%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 10%-38% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Men and Women: Colorectal cancer risk: Elevated at 43%-52% – Recommend colonoscopy every 1-2 years starting at …
Permanent link to this article: https://inheritedcancer.net/post4120/
ICARE Social Media Post March 2020
Cancer Treatment in Childhood and Treatment-Associated Polyposis
ICARE Social Media Post March 2020
Cancer Treatment in Childhood and Treatment-Associated Polyposis
Treatment-associated polyposis (TAP) should be considered in patients who develop many colon polyps after treatment for a childhood or young adulthood cancer but do not have an identified mutation in a hereditary cancer gene. A recent study reported that 35% of patients with TAP developed over 50 colorectal polyps, and 94% had multiple types of …
Permanent link to this article: https://inheritedcancer.net/post32720/
ICARE Social Media Post March 2020
PMS2: Cancer Risks and Risk Management
ICARE Social Media Post March 2020
PMS2: Cancer Risks and Risk Management
Gene: PMS2 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 0%-15% – Consider risk-reducing hysterectomy. Men and Women: Colorectal cancer risk: Elevated at 12%-20% – Recommend colonoscopy every 1-2 years starting at age 20-25 Gastric cancer risk: Not well established – Consider upper endoscopy every 3-5 years beginning at …
Permanent link to this article: https://inheritedcancer.net/post32420/
ICARE Social Media Post March 2020
Study Based on ICARE Participants with ATM and CHEK2 Mutations
ICARE Social Media Post March 2020
Study Based on ICARE Participants with ATM and CHEK2 Mutations
Women with ATM and CHEK2 mutations have a lifetime breast cancer risk greater than 20%, which is the threshold at which screening through a breast MRI is recommended. A recently published study based on ICARE participants with ATM and CHEK2 mutations suggested that most female family members of ATM and CHEK2 mutation carriers do not …
Permanent link to this article: https://inheritedcancer.net/post32020/
ICARE Social Media Post March 2020
MSH6: Cancer Risks and Risk Management
ICARE Social Media Post March 2020
MSH6: Cancer Risks and Risk Management
Gene: MSH6 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: 17%-46% – Consider risk-reducing hysterectomy. Ovarian cancer risk: 1%-11% – Evidence is insufficient to make specific recommendations. Men and Women: Colorectal cancer risk: 15%-44% – Recommend colonoscopy every 1-2 years starting at age 20-25. Gastric cancer risk: 0%-5% – Consider upper …
Permanent link to this article: https://inheritedcancer.net/post31720/
ICARE Social Media Post March 2020
Polygenic Risk Score and Colon Cancer Risk
ICARE Social Media Post March 2020
Polygenic Risk Score and Colon Cancer Risk
A Polygenic Risk Score (PRS) is calculated using genetic differences throughout someoneโs DNA, in combination with clinical and family history of cancer. This score, alongside environmental and lifestyle risk factors, may help to identify people who might benefit from screening at an earlier age. Important facts about PRS: – It does NOT look for changes …
Permanent link to this article: https://inheritedcancer.net/post31320/
ICARE Social Media Post March 2020
MSH2: Cancer Risks and Risk Management
ICARE Social Media Post March 2020
MSH2: Cancer Risks and Risk Management
Gene: MSH2 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 21%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 10%-38% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Men and Women: Colorectal cancer risk: Elevated at 43%-52% – Recommend colonoscopy every 1-2 years starting at …
Permanent link to this article: https://inheritedcancer.net/post31020/
ICARE Social Media Post March 2020
Colon Cancer and Polyp Risks
ICARE Social Media Post March 2020
Colon Cancer and Polyp Risks
New colon cancer and polyposis genes recently identified include NTHL1, POLE, POLD1, MSH3, and RNF43. Previous studies suggest these genes raise the risk for colon cancer and polyposis; however, recent data suggest that environmental factors may also play an important role in risk. Ultimately, these genes account for a very small fraction of polyposis cases. …
Permanent link to this article: https://inheritedcancer.net/post3620/
ICARE Social Media Post March 2020
MLH1: Cancer Risks and Risk Management
ICARE Social Media Post March 2020
MLH1: Cancer Risks and Risk Management
Gene: MLH1 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 43%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 5%-20% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Breast cancer risk: Elevated at 12%-17% – Manage same as general population. Men and Women: Colorectal cancer …
Permanent link to this article: https://inheritedcancer.net/post3320/
ICARE Social Media Post February 2020
Advances in Treatment: Plexiform Neurofibromas in NF1
ICARE Social Media Post February 2020
Advances in Treatment: Plexiform Neurofibromas in NF1
The FDA has granted a breakthrough therapy designation to selumetinib, a MEK inhibitor, for treatment of inoperable plexiform neurofibromas. These types of neurofibromas are almost exclusively seen in individuals with neurofibromatosis type 1 (NF1). These plexiform neurofibromas are benign tumors on the nerve sheaths and can develop anywhere in the body. These tumors typically cause …
Permanent link to this article: https://inheritedcancer.net/post22820/
ICARE Social Media Post February 2020
Genetic Testing in Tumors versus Genetic Testing for Cancer Risk
ICARE Social Media Post February 2020
Genetic Testing in Tumors versus Genetic Testing for Cancer Risk
There are different types of genetic/DNA tests offered to patients with cancer: 1) Tumor tests, mainly done to guide cancer treatment. 2) Blood or saliva tests (on normal DNA that individual was born with) to identify inherited cancer predisposition, which may also guide cancer treatment in some instances. Genetic testing of the tumor detects mutations …
Permanent link to this article: https://inheritedcancer.net/post22620/
ICARE Newsletter Winter 2020
Community Spotlight
ICARE Newsletter Winter 2020
Community Spotlight
I was diagnosed with breast cancer in December 2018 and was found to be PALB2+. The PALB2 gene had not been tested for when my older sister was diagnosed with breast cancer and had genetic testing done four years earlier. This was new! My cancer was very similar to my sisterโs, but being PALB2+ changed …
Permanent link to this article: https://inheritedcancer.net/spotlightnlw2020/
ICARE Newsletter Winter 2020
Treatment Advances Among Those with Inherited Prostate Cancer Predisposition
ICARE Newsletter Winter 2020
Treatment Advances Among Those with Inherited Prostate Cancer Predisposition
A recent study reported a high complete response rate among men with a BRCA1/2 mutation with metastatic, castration-resistant prostate cancer who were treated with niraparib (a PARP inhibitor) of 63% compared to 17% in the non-BRCA1/2 group.1 Based on this data, the Federal Drug Administration (FDA) granted breakthrough therapy designation to niraparib on October 3, …
Permanent link to this article: https://inheritedcancer.net/3nlw2020/
ICARE Newsletter Winter 2020
New Study Based on ICARE Participants with ATM & CHEK2 Mutations
ICARE Newsletter Winter 2020
New Study Based on ICARE Participants with ATM & CHEK2 Mutations
We are excited to tell you about our recently published results based solely on data from ICARE participants with ATM and CHEK2 mutations. Our findings suggest most female family members of ATM and CHEK2 mutation carriers do not qualify for breast MRI screening based on family cancer history alone. This emphasizes the need to share …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-winter-2020new-study-based-on-icare-participants-with-atm-chek2-mutations/
ICARE Newsletter Winter 2020
Treatment Advances Among Those with Inherited Pancreatic Cancer Predisposition
ICARE Newsletter Winter 2020
Treatment Advances Among Those with Inherited Pancreatic Cancer Predisposition
Results from a recent study showed olaparib (a PARP inhibitor) nearly doubled the progression-free survival in BRCA1/2 carriers with metastatic pancreatic cancer.1 Based on this data, the FDA approved the use of olaparib as a first-line maintenance treatment in BRCA1/2 carriers with metastatic, platinum-sensitive pancreatic cancer. This represents another treatment advance in pancreatic cancer and …
Permanent link to this article: https://inheritedcancer.net/2nlw2020/
ICARE Newsletter Winter 2020
PALB2 Mutations & Cancer Risk
ICARE Newsletter Winter 2020
PALB2 Mutations & Cancer Risk
A newly published study of 524 families with pathogenic PALB2 mutations from around the world, including almost 50 ICARE participants, represents the largest, most comprehensive effort to evaluate cancer risks.1 Results showed increased risks for female breast cancer (53%), ovarian cancer (5%), pancreatic cancer (2-3%), and male breast cancer (1%). Findings did not suggest higher …
Permanent link to this article: https://inheritedcancer.net/6nlw2020/
ICARE Newsletter Winter 2020
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
ICARE Newsletter Winter 2020
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
There were significant updates and restructuring of the guidelines, with some highlights included below: Substantial reorganization of the guidelines as follows: Now organized by organ site, rather than primarily by certain high penetrance genes Focused efforts to simplify genetic testing criteria Only one flow diagram included, to outline the โgenetic testing processโ Following scenarios now …
Permanent link to this article: https://inheritedcancer.net/1nlw2020/
ICARE Newsletter Winter 2020
Updated Pancreatic Cancer Screening Guidelines through CAPS Consortium
ICARE Newsletter Winter 2020
Updated Pancreatic Cancer Screening Guidelines through CAPS Consortium
The International Cancer of the Pancreas Screening (CAPS) Consortium recently published updated recommendations about pancreatic cancer screening through MRI/magnetic retrograde cholangiopancreatography (MRCP) and/or an endoscopic ultrasound (EUS).1 Specifically, these guidelines now recommend that individuals with a CDKN2A or STK11 mutation begin screening at age 40. Screening for individuals with a BRCA1/2, ATM, PALB2, MLH1, or …
Permanent link to this article: https://inheritedcancer.net/4nlw2020/
ICARE Newsletter Winter 2020
Ask the Expert
ICARE Newsletter Winter 2020
Ask the Expert
Through each newsletter, we give our participants an opportunity to have their questions answered by experts. If you have a question you would like addressed, please email the study team at ICARE@InheritedCancer.net for consideration in future newsletters. The following question was addressed by Ben Ho Park, MD, PhD, who is the Donna S. Hall Chair …
Permanent link to this article: https://inheritedcancer.net/8nlw2020/
ICARE Newsletter Winter 2020
Lynch Syndrome Cancer Risks Across Genes
ICARE Newsletter Winter 2020
Lynch Syndrome Cancer Risks Across Genes
A worldwide study reporting on cancer risks among individuals with mutations in Lynch syndrome genes showed that there are substantial differences in cancer risks across the various genes.1 Specifically, the risk for colorectal cancer in those with MLH1, MSH2, and MSH6 mutations was substantially higher than what was seen for those with PMS2 mutations. Additionally, …
Permanent link to this article: https://inheritedcancer.net/5nlw2020/
ICARE Social Media Post February 2020
PMS2 and MSH6 Colorectal Cancer Risks
ICARE Social Media Post February 2020
PMS2 and MSH6 Colorectal Cancer Risks
Individuals with Lynch syndrome have an increased risk of colorectal cancer (CRC) and other cancers. The level of CRC risk is different based on which gene they have a mutation in. Of note, MLH1 and MSH2 carriers have the highest risk of colorectal cancer, generally in the range of 43%-52% by age 70. A recent …
Permanent link to this article: https://inheritedcancer.net/post22020/
ICARE Social Media Post February 2020
Ovarian Cancer Risks in BRCA1/2
ICARE Social Media Post February 2020
Ovarian Cancer Risks in BRCA1/2
The risk of ovarian cancer is raised in women with BRCA1/2 mutations. Recent findings suggest that higher body mass index (BMI) may further raise the risk of ovarian cancer in premenopausal BRCA1/2 carriers. Note that all women with BRCA1/2 mutations are at high risk for ovarian cancer, and should follow current National Comprehensive Cancer Network …
Permanent link to this article: https://inheritedcancer.net/post21820/
ICARE Social Media Post February 2020
Characteristics and Patterns of Spread for BRCA-associated Breast Cancers
ICARE Social Media Post February 2020
Characteristics and Patterns of Spread for BRCA-associated Breast Cancers
BRCA1/2 have distinct characteristics and patterns of spread. A recent study evaluated the characteristics of BRCA1/2 carriers and found that 73% ofBRCA1-associated breast cancers were triple negative; and 72% of BRCA2-associated breast cancers were hormone receptor positive. There were also distinct pattern of spread of breast cancer, with BRCA1 carriers more likely to experience lung …
Permanent link to this article: https://inheritedcancer.net/post21320/
ICARE Social Media Post February 2020
Medication Use for Risk Reduction
ICARE Social Media Post February 2020
Medication Use for Risk Reduction
Based on studies that show benefits of estrogen and androgen blockers in reducing breast cancer risk in high-risk women, the United States Preventative Service Task Force (USPSTF) recommends that clinicians offer risk-reducing medications to women at increased risk for breast cancer; however, they recommend against routine use of these medications in average-risk women. Hormone receptor …
Permanent link to this article: https://inheritedcancer.net/post21120/
ICARE Social Media Post February 2020
Lynch Syndrome Cancer Risks Across Genes
ICARE Social Media Post February 2020
Lynch Syndrome Cancer Risks Across Genes
A worldwide study suggests that risks for cancers for the various Lynch syndrome genes have some differences. The risk of colorectal cancer for those with a mutation in the MLH1, MSH2 and MSH6 genes is higher than what is seen for carriers of a PMS2 mutation. Additionally, men with MSH2 gene mutations have a higher …
Permanent link to this article: https://inheritedcancer.net/post2720/
ICARE Social Media Post February 2020
Differences in Pancreatic Cancer Screening Recommendations from the National Comprehensive Cancer Network (NCCN) and the International Cancer of the Pancreas Screening (CAPS) Consortium
ICARE Social Media Post February 2020
Differences in Pancreatic Cancer Screening Recommendations from the National Comprehensive Cancer Network (NCCN) and the International Cancer of the Pancreas Screening (CAPS) Consortium
The National Comprehensive Cancer Network (NCCN) and the International Cancer of the Pancreas Screening (CAPS) Consortium recently updated pancreatic cancer screening recommendations. However, there are some differences between these recommendations. Specifically, screening with annual MRI/magnetic retrograde cholangiopancreatography (MRCP) and/or endoscopic ultrasound (EUS) is recommended as follows for NCCN versus CAPS: STK11 regardless of family history: …
Permanent link to this article: https://inheritedcancer.net/post2620/
ICARE Social Media Post February 2020
Updated Pancreatic Cancer Screening Guidelines through the International Cancer of the Pancreas Screening (CAPS) Consortium
ICARE Social Media Post February 2020
Updated Pancreatic Cancer Screening Guidelines through the International Cancer of the Pancreas Screening (CAPS) Consortium
The International Cancer of the Pancreas Screening (CAPS) Consortium recently published updated pancreatic cancer screening recommendations. The recommendations include: Screening with MRI/magnetic retrograde cholangiopancreaography (MRCP) and/or endoscopic ultrasound (EUS) The screening was recommended for the following individuals: CDKN2A and STK11 mutation carriers starting at age 40 BRCA1/2, ATM, PALB2, MLH1, and MSH2 mutation carriers (if …
Permanent link to this article: https://inheritedcancer.net/post2420/
ICARE Social Media Post January 2020
Advances in Treatment for Lynch Syndrome-Related Endometrial Cancer
ICARE Social Media Post January 2020
Advances in Treatment for Lynch Syndrome-Related Endometrial Cancer
A recent phase II study showed increased response to an immunotherapy drug (avelumab), in women with endometrial cancer with mismatch repair deficiency. Among women with Lynch Syndrome, the risk for endometrial cancer (which often has mismatch repair deficiency) is raised. This new study shows promising treatment options for women with endometrial cancer and Lynch syndrome …
Permanent link to this article: https://inheritedcancer.net/13020/
ICARE Social Media Post January 2020
New Gene: DUOX2
ICARE Social Media Post January 2020
New Gene: DUOX2
DUOX2 represents a newly identified gene that might predispose patients to thyroid cancer (specifically, โnon-medullaryโ thyroid cancer). The specific gene change (or โmutationโ) that leads to thyroid cancer predisposition is known as Y1203H Additional studies are needed to confirm this association. Check it out at ASCO Post: https://tinyurl.com/sw3ew63 ๐จ๐ซ you can access the article at …
Permanent link to this article: https://inheritedcancer.net/post12420/
ICARE Social Media Post January 2020
New Gene: RABL3
ICARE Social Media Post January 2020
New Gene: RABL3
About 10% of pancreatic cancers are thought to be the result of an inherited mutation. All of the genes that predispose patients to pancreatic cancers have not yet been discovered. Recently, a new gene known as RABL3 was linked to pancreatic cancer. This gene may increase the risk of hereditary pancreatic cancer. Additional studies are …
Permanent link to this article: https://inheritedcancer.net/post12120/
ICARE Social Media Post January 2020
Ovarian Cancer Screening in BRCA1 Carriers
ICARE Social Media Post January 2020
Ovarian Cancer Screening in BRCA1 Carriers
A new study of Polish BRCA1 carriers showed that screening through transvaginal ultrasound was not effective or reliable in detecting ovarian cancer early. Consequently, preventive oophorectomy remains the only proven method to lower ovarian cancer risks and increase survival. Check out the article at: https://www.ncbi.nlm.nih.gov/pubmed/31500890. Check out the NCCN ovarian cancer screening recommendations for BRCA1 …
Permanent link to this article: https://inheritedcancer.net/post11720/
ICARE Social Media Post January 2020
Racial Disparities in Genetic Testing for Women with Ovarian Cancer
ICARE Social Media Post January 2020
Racial Disparities in Genetic Testing for Women with Ovarian Cancer
Women of non-European ancestry diagnosed with ovarian cancer have lower rates of referral for genetic testing despite current national guidelines stating ALL women with ovarian cancer and/or a close-blood relative with ovarian cancer should be offered genetic counseling and testing. One study reported that only 1/3 of Black, Latina, and Asian women were referred for …
Permanent link to this article: https://inheritedcancer.net/post11620/
ICARE Social Media Post January 2020
Polygenic Risk Scores
ICARE Social Media Post January 2020
Polygenic Risk Scores
A Polygenic Risk Score (PRS) is calculated using genetic differences throughout someoneโs DNA, in combination with clinical and family history of cancer. This unique type of score may be utilized to calculate the lifetime risk of breast cancer. Important facts about PRSโs: Different from BRCA1/2 testing, which look for changes in these specific genes Should …
Permanent link to this article: https://inheritedcancer.net/post11420/
ICARE Social Media Post January 2020
Women with BRCA1/2: Risk-reducing Mastectomy versus Screening
ICARE Social Media Post January 2020
Women with BRCA1/2: Risk-reducing Mastectomy versus Screening
In a study of 5000 healthy female BRCA1/2 carriers (without a breast cancer diagnosis): BRCA1 carriers: after an average of over 10 years follow-up, survival was higher in those who had bilateral mastectomy (99.7%) compared to those who had breast screening through mammograms and breast MRIs (93%). BRCA2 carriers: no significant differences were seen between …
Permanent link to this article: https://inheritedcancer.net/post11020/
ICARE Social Media Post January 2020
Celebrating 10 Years of ICARE
ICARE Social Media Post January 2020
Celebrating 10 Years of ICARE
Happy New Year! 2020 represents a decade for ICARE We are celebrating 10 years of research, education, and engagement, through which we have enrolled nearly 3500 participants, including over 2000 gene mutation carriers, disseminated 15 newsletters, led and collaborated on multiple research projects, and impacted individuals affected by inherited cancer predisposition all over the …
Permanent link to this article: https://inheritedcancer.net/post1920/
ICARE Social Media Post January 2020
Advances in Treatment for Pancreatic Cancer in BRCA Carriers
ICARE Social Media Post January 2020
Advances in Treatment for Pancreatic Cancer in BRCA Carriers
The FDA approved the use of olaparib, a PARP inhibitor, as first-line maintenance treatment in BRCA1/2 carriers with metastatic, platinum-sensitive, pancreatic cancer. Platinum-sensitive cancer is a cancer that responds to treatment with drugs that contain the metal platinum, such as carboplatin or cisplatin. Olaparib showed to nearly double the progression-free survival in BRCA1/2 carriers with …
Permanent link to this article: https://inheritedcancer.net/post1320/
ICARE Social Media Post December 2019
Evaluation of PARP Inhibitors in BRCA-Associated Prostate Cancer
ICARE Social Media Post December 2019
Evaluation of PARP Inhibitors in BRCA-Associated Prostate Cancer
The FDA granted breakthrough therapy designation to niraparib (a PARP inhibitor) for the treatment of men with BRCA1/2 positive, metastatic castration-resistant, and heavily pre-treated prostate cancer. Results from a recent study show a 63% complete response rate in men with BRCA1/2 positive, metastatic castration-resistant prostate cancer treated with niraparib compared to 17% in the non- …
Permanent link to this article: https://inheritedcancer.net/post122019/
ICARE Social Media Post December 2019
PALB2 Mutations and Cancer Risk
ICARE Social Media Post December 2019
PALB2 Mutations and Cancer Risk
A new published study of 524 families with PALB2 mutations, including our very own ICARE participants, from around the world showed increased risks of female breast, ovarian, pancreatic, and male breast cancer. The level of risk for female breast cancer is enough to recommend cancer risk management. Cancer risk management includes screening or risk-reducing surgery. …
Permanent link to this article: https://inheritedcancer.net/post121619/
ICARE Social Media Post December 2019
American College of Medical Genetics and Genomics: Points-to-Consider Document: โIs there Evidence to Support BRCA1/2 and Other Inherited Breast Cancer Genetic Testing for all Breast Cancer Patients?โ
ICARE Social Media Post December 2019
American College of Medical Genetics and Genomics: Points-to-Consider Document: โIs there Evidence to Support BRCA1/2 and Other Inherited Breast Cancer Genetic Testing for all Breast Cancer Patients?โ
The American College of Medical Genetics and Genomics (ACMG) put forth a Points-to-Consider document: โIs there Evidence to Support BRCA1/2 and Other Inherited Breast Cancer Genetic Testing for all Breast Cancer Patients?โ The document discusses: 1) Current data to support testing in breast cancer patients …
Permanent link to this article: https://inheritedcancer.net/post121319/
ICARE Social Media Post December 2019
Patient Reported Outcomes In A Study of PARP Inhibitors in BRCA Carriers with Metastatic Breast Cancer
ICARE Social Media Post December 2019
Patient Reported Outcomes In A Study of PARP Inhibitors in BRCA Carriers with Metastatic Breast Cancer
Did you know? PROs are impacting treatment advances in metastatic breast cancer. Olaparib increased progression-free survival among BRCA carriers with metastatic HER2- breast cancer. Thanks to patient reported outcomes, a new study now suggests it also improved patientsโ quality of life! Check it out the new article published in October 2019 directly at https://www.ncbi.nlm.nih.gov/pubmed/31446213!
Permanent link to this article: https://inheritedcancer.net/post12819/
ICARE Social Media Post December 2019
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial Breast, Ovarian, and Pancreatic Guidelines (V1.2020)
ICARE Social Media Post December 2019
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial Breast, Ovarian, and Pancreatic Guidelines (V1.2020)
We are excited to share the latest version of the NCCN Genetic/Familial Breast, Ovarian and Pancreatic Guidelines (V1.2020), which were just updated. Some of the changes made include: PALB2 was added as a high penetrance gene (similar to BRCA1, BRCA2, CDH1, PTEN and TP53) It is appropriate to consider risk reducing mastectomy for cancer risk management …
Permanent link to this article: https://inheritedcancer.net/post12419/
ICARE Social Media Post December 2019
Explaining Patient Reported Outcomes
ICARE Social Media Post December 2019
Explaining Patient Reported Outcomes
The National Quality Forum defines patient reported outcomes (PROs) as โany report of the status of a patientโs health condition that comes directly from the patient.โ PROs have the potential to increase overall outcomes and care process and enhance patient and family centered care.
Permanent link to this article: https://inheritedcancer.net/post12319/
ICARE Social Media Post November 2019
Educational Resources: The Family Link Between Breast and Ovarian Cancer in Black Women
ICARE Social Media Post November 2019
Educational Resources: The Family Link Between Breast and Ovarian Cancer in Black Women
The differences seen in access to healthcare across different racial groups are known as health disparities. To address the gap in awareness, we have pursued efforts to raise awareness about inherited breast cancer among African Americans. We are excited to introduce you to another invaluable resource, the Breast Cancer Genetics Research and Education for African American …
Permanent link to this article: https://inheritedcancer.net/post11119/
ICARE Social Media Post November 2019
High Frequency of BRCA in Unselected Women with Metastatic Breast Cancer
ICARE Social Media Post November 2019
High Frequency of BRCA in Unselected Women with Metastatic Breast Cancer
Did you know? National practice guidelines currently recommend ALL women with metastatic (HER2-) breast cancer to get genetic testing for inherited cancer (including BRCA1/2 testing), because it can guide eligibility for treatment with PARP inhibitors. A new study led by our colleague at the Vanderbilt-Ingram Cancer Center, Dr. Ben Park, suggests that more women with …
Permanent link to this article: https://inheritedcancer.net/post110719/
ICARE Social Media Post October 2019
Lifestyle Factors Associated with Familial and Inherited Breast Cancer Risks
ICARE Social Media Post October 2019
Lifestyle Factors Associated with Familial and Inherited Breast Cancer Risks
Body mass index (BMI) is an indicator of fat content in the body. A lower body mass index may reduce breast cancer risk in women, including those with a family history of breast cancer. However, a new study reported that higher BMI also increases breast cancer risk in the general population and those with a …
Permanent link to this article: https://inheritedcancer.net/post102919/
ICARE Social Media Post October 2019
Physical Activity Associated with Familial and Inherited Breast Cancer Risks
ICARE Social Media Post October 2019
Physical Activity Associated with Familial and Inherited Breast Cancer Risks
BRCA1/2 carriers may benefit from physical activity to reduce breast cancer risks, just like women in the general population! We know that women in the general population benefit from physical activity to reduce their breast cancer risk, but a recent study showed that this benefit also extends to those with a BRCA1/2 mutation and those with …
Permanent link to this article: https://inheritedcancer.net/post102819/
ICARE Social Media Post October 2019
BRCA Testing In Black Women
ICARE Social Media Post October 2019
BRCA Testing In Black Women
Did you know? Although BRCA testing has been around for over TWO decades, not all populations have benefitted equally from testing. In fact, our previous research has shown that black patients are less aware of BUT interested in genetic testingโฆwhen they know about it. In addition, healthcare providers are less likely to identify and suggest …
Permanent link to this article: https://inheritedcancer.net/post102419/
ICARE Social Media Post October 2019
Inherited Breast Cancer Among Latina Women
ICARE Social Media Post October 2019
Inherited Breast Cancer Among Latina Women
Latina women are at risk for inherited breast cancer: Breast cancer mortality rates are higher among Latina women compared to non-Hispanic White women. Latina women also have a higher prevalence of triple-negative breast cancer when compared to with non-Hispanic White women. Latina women are diagnosed with breast cancer at earlier ages, 56 years versus 63 …
Permanent link to this article: https://inheritedcancer.net/post102319/
ICARE Social Media Post October 2019
Advances in Treatment for Advanced Breast Cancer in BRCA Carriers
ICARE Social Media Post October 2019
Advances in Treatment for Advanced Breast Cancer in BRCA Carriers
Monotherapy with PARP inhibitors is FDA-approved for patients with metastatic breast cancer with BRCA mutations. BUT, does adding additional drugs (called โcombination therapyโ) help? In BRCA carriers with metastatic breast cancer, the combination of veliparib AND chemotherapy with platinum-based agents (carboplatin) and taxanes (paclitaxel) led to a longer duration of progression free survival (disease that …
Permanent link to this article: https://inheritedcancer.net/post101819/
ICARE Social Media Post October 2019
Advances in Early Stage Breast Cancer Treatment for BRCA Carriers
ICARE Social Media Post October 2019
Advances in Early Stage Breast Cancer Treatment for BRCA Carriers
New benefits from a PARP inhibitor, talazoparib, among BRCA carriers with early stage breast cancer. The current FDA approvals for the use of PARP inhibitors is limited to women with metastatic (stage IV) breast cancer. These drugs are being tested in early stage breast cancer to shrink down the tumor (called neoadjuvant treatment) before surgery …
Permanent link to this article: https://inheritedcancer.net/post101519/
ICARE Social Media Post October 2019
Male Breast Cancer Risk
ICARE Social Media Post October 2019
Male Breast Cancer Risk
Did you know? Beyonceโs father, Matthew Knowles, was diagnosed with breast cancer. He states, โwe used to think this was only an issue for women, but this is male or female.โ According to CBS news, โhe is hoping that sharing his story as man with breast cancer will shine a light on the risk men …
Permanent link to this article: https://inheritedcancer.net/post10619/
ICARE Social Media Post September 2019
Family Sharing Resources: GeneSHARE
ICARE Social Media Post September 2019
Family Sharing Resources: GeneSHARE
With the tremendous advances in gene-based care among those with inherited cancer risk, we are trying to develop tools and strategies to make it easier for more people to benefit from genetic education and testing. We are proud to introduce you to GeneSHARE, a free online toolkit for YOU, to help share positive test results …
Permanent link to this article: https://inheritedcancer.net/post91319/
ICARE Newsletter Summer 2019
Ask the Expert
ICARE Newsletter Summer 2019
Ask the Expert
The following question was addressed by Gillian Hooker, PhD, ScM, LCGC, who is the president-elect for the National Society of Genetic Counselors, Adjunct Associate Professor in the Division of Genetic Medicine at the Vanderbilt University Medical Center, and the Vice President of Clinical Development for Concert Genetics in Nashville, TN. Q. Why was the BRCA1/2 …
Permanent link to this article: https://inheritedcancer.net/10nls2019/
ICARE Newsletter Summer 2019
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines
ICARE Newsletter Summer 2019
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines
(Version 1.2019, posted July 3, 2019) For Individuals with Lynch Syndrome: The cancer risk table was updated: Addition of new cancer risks by specific genes: breast and bladder cancers Updates of cancer risks by specific genes: ovarian, prostate, gastric, pancreatic, urothelial, small bowel, and brain/CNS cancers Removal of reference to sebaceous neoplasms Recommendations for cancer …
Permanent link to this article: https://inheritedcancer.net/1nls2019/
ICARE Newsletter Summer 2019
Ovarian Cancer Treatment Advances for BRCA1/2 Carriers
ICARE Newsletter Summer 2019
Ovarian Cancer Treatment Advances for BRCA1/2 Carriers
A recently reported study of women with ovarian cancer and homologous recombination deficiency (HRD) who received a PARP inhibitor (niraparib) as fourth line or later treatment showed potential clinical benefit. Specifically, median overall survival after treatment was 19 months in the HRD-positive group (including those with BRCA1/2 mutations) compared to 15.5 months in the HRD-negative …
Permanent link to this article: https://inheritedcancer.net/4nls2019/
ICARE Newsletter Summer 2019
New Information About Cancer Risks for Inherited Cancer Genes: BRCA1/2
ICARE Newsletter Summer 2019
New Information About Cancer Risks for Inherited Cancer Genes: BRCA1/2
Looking at pregnancy history and breast cancer risk, a recent study of almost 8,000 women with BRCA1/2 mutations evaluated breast cancer risks related to pregnancy.1 Findings suggested the overall number of pregnancies was not associated with breast cancer risk in BRCA1 carriers; however, BRCA1 carriers with one pregnancy were at higher risk for breast cancer …
Permanent link to this article: https://inheritedcancer.net/6nls2019/
ICARE Newsletter Summer 2019
Community Spotlight
ICARE Newsletter Summer 2019
Community Spotlight
Life was great at 45. I had nothing more than a few headaches and was a tad overweight. After a friend was diagnosed with breast cancer, I realized I had not had a mammogram in a couple of years, so I scheduled an appointment. One mass was found, but it was benign and nothing to …
Permanent link to this article: https://inheritedcancer.net/spotlightnls2019/
ICARE Newsletter Summer 2019
Pancreatic Cancer Treatment Advances for BRCA1/2 Carriers
ICARE Newsletter Summer 2019
Pancreatic Cancer Treatment Advances for BRCA1/2 Carriers
Results from a clinical trial of individuals with a BRCA1/2 mutation and pancreatic cancer showed that patients who received a PARP inhibitor (olaparib) for maintenance treatment had almost half the risk of their disease progressing when compared to receiving a placebo.1 In fact, after 2 years, 22.1% of patients who received olaparib had no disease …
Permanent link to this article: https://inheritedcancer.net/3nls2019/
ICARE Newsletter Summer 2019
New Information About Cancer Risks for Inherited Cancer Genes: CHEK2
ICARE Newsletter Summer 2019
New Information About Cancer Risks for Inherited Cancer Genes: CHEK2
In a study of inherited mutations in the CHEK2 gene, findings suggest there were two specific mutations that could predispose men to testicular germ cell tumors (TGCT). Specifically, 205 men with these tumors were tested for 48 DNA repair genes, and findings were then tested in other patient populations. These findings suggest that CHEK2 mutations …
Permanent link to this article: https://inheritedcancer.net/7nls2019/
ICARE Newsletter Summer 2019
New Information About Cancer Risks for Inherited Cancer Genes: DICER1
ICARE Newsletter Summer 2019
New Information About Cancer Risks for Inherited Cancer Genes: DICER1
In a study of over 100 individuals with a DICER1 mutation, findings suggest that 5.3% of individuals had developed cancer by age 10, and 19.3% by age 50. After age 10, cancer risks for women were higher compared to men. Specific cancers for which risks were high included gynecologic and thyroid cancers. These findings are …
Permanent link to this article: https://inheritedcancer.net/8nls2019/
ICARE Newsletter Summer 2019
Prostate Cancer Treatment Advances for BRCA1/2 Carriers
ICARE Newsletter Summer 2019
Prostate Cancer Treatment Advances for BRCA1/2 Carriers
There is now information to suggest that identifying inherited mutations in DNA repair genes, such as BRCA1/2 and other genes, in men with metastatic prostate cancer may open doors for other treatment options. Results of a phase 2 clinical trial among men with metastatic and heavily pre-treated prostate cancer were presented at the American Society …
Permanent link to this article: https://inheritedcancer.net/2nls2019/
ICARE Newsletter Summer 2019
Expansion of Criteria for BRCA1/2 Testing through the USPSTF
ICARE Newsletter Summer 2019
Expansion of Criteria for BRCA1/2 Testing through the USPSTF
The U.S. Preventive Services Task Force (USPSTF) came out with new genetic testing guidelines for the BRCA1/2 genes, which has garnered substantial media attention. This task force consists of a team of primary care and preventive medicine healthcare experts to lower the chance of a conflict of interest (which is also the reason that subspecialty …
Permanent link to this article: https://inheritedcancer.net/5nls2019/
ICARE Newsletter Summer 2019
Expanding Our Thinking About Cancer Risks in TP53 Mutations and Li-Fraumeni Syndrome
ICARE Newsletter Summer 2019
Expanding Our Thinking About Cancer Risks in TP53 Mutations and Li-Fraumeni Syndrome
Since expanded genetic testing has become available through multigene panel tests, studies have suggested that many people identified to have TP53 mutations do not have a typical personal or family history, which is usually seen with Li-Fraumeni syndrome (LFS). A recent study looking at over 300 individuals with TP53 mutations (identified through multi-gene panel testing) …
Permanent link to this article: https://inheritedcancer.net/11nls2019/
ICARE Newsletter Summer 2019
New Information About Cancer Risks for Inherited Cancer Genes: HAUS6, KANLS1, PCR1
ICARE Newsletter Summer 2019
New Information About Cancer Risks for Inherited Cancer Genes: HAUS6, KANLS1, PCR1
Through a study of over 13,000 patients with serous ovarian cancers and almost 41,000 controls, 34 genes that raise the risk for ovarian cancer were identified. Additional laboratory studies were conducted to further characterize some of these genes, suggesting that three of these new genes may be essential (HAUS6, KANLS1, and PRC1). This study has …
Permanent link to this article: https://inheritedcancer.net/9nls2019/
ICARE Newsletter Winter 2019
Other Advances in Cancer Treatment Among Cancer Patients with Inherited Disease: Familial Adenomatous Polyposis (FAP)
ICARE Newsletter Winter 2019
Other Advances in Cancer Treatment Among Cancer Patients with Inherited Disease: Familial Adenomatous Polyposis (FAP)
A new drug (sorafenib) showed promising results among patients with desmoid tumors, which are a type of tumor for which patients with Familial Adenomatous Polyposis (FAP) due to APC gene mutations are at risk. These tumors frequently grow and encompass internal organs and can be hard to remove surgically. The newly published research showed that …
Permanent link to this article: https://inheritedcancer.net/9nlw2019/
ICARE Newsletter Winter 2019
Advances in Biomarkers to Detect Pancreatic Cancer Early
ICARE Newsletter Winter 2019
Advances in Biomarkers to Detect Pancreatic Cancer Early
Early detection of pancreatic cancer is tremendously important, given that most patients who develop the disease are diagnosed at a later stage of the disease when it is usually incurable. Although screening through imaging studies has been proposed (i.e., magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound),1 data to support this type of screening as an …
Permanent link to this article: https://inheritedcancer.net/12nlw2019/
ICARE Newsletter Winter 2019
Community Spotlight
ICARE Newsletter Winter 2019
Community Spotlight
When I was 50 years old I was in pretty good physical shape and I thought I was finally getting six pack abs. I was wrong โ those abs were a large football sized tumor, along with a variety of smaller tumors. I was diagnosed with Stage 4 ovarian cancer. I had a hysterectomy and fibroid removal …
Permanent link to this article: https://inheritedcancer.net/spotlightnlw2019/
ICARE Newsletter Winter 2019
Other Advances in Cancer Treatment Among Cancer Patients with Inherited Disease: Lynch Syndrome
ICARE Newsletter Winter 2019
Other Advances in Cancer Treatment Among Cancer Patients with Inherited Disease: Lynch Syndrome
Pertaining to metastatic prostate cancer, recently published data reported 8.1% of men with advanced prostate cancer had evidence of mismatch repair (MMR) mutations in their tumors. These types of mutations are frequently seen in tumors among Lynch syndrome patients. In addition, men with this type of tumor had much poorer survival. Tumors with MMR defects …
Permanent link to this article: https://inheritedcancer.net/7nlw2019/
ICARE Newsletter Winter 2019
New Genes: GALNT12
ICARE Newsletter Winter 2019
New Genes: GALNT12
A gene called GALNT12 may be yet another inherited colorectal cancer gene,1 as originally suggested by prior studies.2 The current study screened almost 500 colorectal cancer patients and identified 8 rare variants that may be disease causing. The frequency of variants among colorectal cancer patients was much higher than that observed among population-matched healthy controls, …
Permanent link to this article: https://inheritedcancer.net/13nlw2019/
ICARE Newsletter Winter 2019
Other Advances in Cancer Treatment Among Cancer Patients with Inherited Disease: von Hippel-Lindau (VHL) Disease
ICARE Newsletter Winter 2019
Other Advances in Cancer Treatment Among Cancer Patients with Inherited Disease: von Hippel-Lindau (VHL) Disease
Additional exciting advances include the results of a new drug (pazopanib) to treat an inherited cancer condition called von Hippel-Lindau Disease (VHL), in which patients are predisposed to kidney cancers, pancreatic tumors, and hemangioblastomas (i.e., tumors involving the blood vessels). Study results showed that among 31 patients with VHL, overall response rate with the drug …
Permanent link to this article: https://inheritedcancer.net/8nlw2019/
ICARE Newsletter Winter 2019
Basal Cell Cancers May Be a Risk Factor to Predict Inherited Cancer Predisposition
ICARE Newsletter Winter 2019
Basal Cell Cancers May Be a Risk Factor to Predict Inherited Cancer Predisposition
An interesting area of progress to identify individuals with inherited risks included a study of over 13,000 individuals with six or more basal cell cancers (BCC) evaluated through a claims database. Results indicated ~20% of these individuals had a germline mutation in a DNA repair gene, including BRCA1/2, PALB2, and the Lynch syndrome genes, among …
Permanent link to this article: https://inheritedcancer.net/10nlw2019/
ICARE Newsletter Winter 2019
New Research and Approvals of PARP Inhibitor Drugs to Treat Prostate Cancer in BRCA Carriers
ICARE Newsletter Winter 2019
New Research and Approvals of PARP Inhibitor Drugs to Treat Prostate Cancer in BRCA Carriers
Treatment among patients with metastatic castration-resistant prostate cancer: A PARP inhibitor (rucaparib) was granted a breakthrough therapy designation in October 2018 for monotherapy (i.e., sole treatment) among men with metastatic castration-resistant prostate cancer (with a BRCA1/2 mutation) who have received at least one prior androgen receptor-directed treatment and taxane-based chemotherapy. This designation was granted based …
Permanent link to this article: https://inheritedcancer.net/3nlw2019/
ICARE Newsletter Winter 2019
Ask the Expert
ICARE Newsletter Winter 2019
Ask the Expert
The following question was addressed by Georgia Wiesner, MD, MS, a nationally renowned clinical cancer geneticist, who is an Ingram Professor of Cancer Research, Professor of Medicine in the Division of Genetic Medicine, and the Director of the Clinical and Translational Hereditary Cancer Program for the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. Q. What are …
Permanent link to this article: https://inheritedcancer.net/14nlw2019/
ICARE Newsletter Winter 2019
New Research and Approvals of PARP Inhibitor Drugs to Treat Breast Cancer in BRCA Carriers
ICARE Newsletter Winter 2019
New Research and Approvals of PARP Inhibitor Drugs to Treat Breast Cancer in BRCA Carriers
Treatment among patients with advanced or metastatic breast cancer: A PARP inhibitor (talazoparib) was approved by the FDA on October 16, 2018 for BRCA carriers with HER2-negative locally advanced or metastatic breast cancer, based on results of the EMBRACA trial outlined in the last ICARE newsletter. Litton JK, et al. N Engl J Med. 2018 …
Permanent link to this article: https://inheritedcancer.net/1nlw2019/
ICARE Newsletter Winter 2019
Expansion of Lynch Syndrome Tumor Spectrum Which May Have Treatment Implications
ICARE Newsletter Winter 2019
Expansion of Lynch Syndrome Tumor Spectrum Which May Have Treatment Implications
Although the Lynch syndrome tumor spectrum is thought to be limited to cancers of the colorectum, endometrium, ovaries, stomach, and a few other cancer types, a recent article suggested there might be a broader tumor spectrum than previously considered. Furthermore, colorectal and endometrial cancers which develop among Lynch syndrome patients frequently are determined on tumor …
Permanent link to this article: https://inheritedcancer.net/6nlw2019/
ICARE Newsletter Winter 2019
Refining Treatment for Aggressive Prostate Cancer in Men with BRCA2
ICARE Newsletter Winter 2019
Refining Treatment for Aggressive Prostate Cancer in Men with BRCA2
A recent study reported that a large proportion of men with aggressive prostate cancer have inherited cancer gene mutations. Specifically, among 400 patients with castration-resistant prostate cancer, 16.2% had a germline mutation in a DNA damage repair gene, including 3% with a BRCA2 mutation. Among BRCA2 carriers, survival was 17.4 months, which was much lower …
Permanent link to this article: https://inheritedcancer.net/5nlw2019/
ICARE Newsletter Winter 2019
New Research and Approvals of PARP Inhibitor Drugs to Treat Ovarian Cancer in BRCA Carriers
ICARE Newsletter Winter 2019
New Research and Approvals of PARP Inhibitor Drugs to Treat Ovarian Cancer in BRCA Carriers
First line maintenance treatment among patients newly diagnosed with advanced ovarian cancer: The results of a trial using a PARP inhibitor (olaparib) as maintenance treatment among ovarian cancer patients with advanced disease, a BRCA mutation, and complete or partial response to platinum-based chemotherapy showed that survival at 3 years was 60% among those who got …
Permanent link to this article: https://inheritedcancer.net/2nlw2019/
ICARE Newsletter Winter 2019
High Proportion of Inherited Genes Detected Among Patients with Advanced Renal Cancer
ICARE Newsletter Winter 2019
High Proportion of Inherited Genes Detected Among Patients with Advanced Renal Cancer
In a study of advanced renal cell cancer patients, inherited cancer gene mutations were identified in 16%, of which 5.5% had mutations in genes related to renal cell cancer. Among the subgroup with non-clear cell renal cancer, about a fifth had an inherited cancer gene mutation, half of which had a gene mutation that could …
Permanent link to this article: https://inheritedcancer.net/4nlw2019/
ICARE Newsletter Winter 2019
Testing Interpretation and Variant Reclassification
ICARE Newsletter Winter 2019
Testing Interpretation and Variant Reclassification
Results of germline genetic testing generally yield three types of test results: Deleterious (positive), Negative (no mutation detected), and Variant of Uncertain Significance (VUS). As more genes are tested, the chance for a positive result goes up, as does the chance of receiving a VUS result.1 VUS results tell us that it remains uncertain whether …
Permanent link to this article: https://inheritedcancer.net/15nlw2019/
ICARE Newsletter Winter 2019
New Online Risk Calculator to More Accurately Predict Breast Cancer Risk
ICARE Newsletter Winter 2019
New Online Risk Calculator to More Accurately Predict Breast Cancer Risk
Prediction of breast cancer risk is important to identify those at highest and lowest risks, to help guide screening. A previously developed risk algorithm called Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) was recently extended to include truncating mutations in the BRCA genes, PALB2, CHEK2, and ATM. This online risk …
Permanent link to this article: https://inheritedcancer.net/11nlw2019/
ICARE Newsletter Summer 2018
The Role of Inherited Genes Increasingly Recognized in Pancreatic Cancer
ICARE Newsletter Summer 2018
The Role of Inherited Genes Increasingly Recognized in Pancreatic Cancer
A number of recent studies have suggested that a substantial number of individuals with pancreatic cancer have a mutation in an inherited cancer gene. In a study of over 300 patients with pancreatic cancer (and with one or two family members with pancreatic cancer), 12% were found to have a mutation in 1 of 11 …
Permanent link to this article: https://inheritedcancer.net/4nls2018/
ICARE Newsletter Summer 2018
Community Spotlight
ICARE Newsletter Summer 2018
Community Spotlight
I was aware from a very young age that breast cancer was part of our family. I knew that my great-grandmother (whom I never met) had breast cancer and my grandmother was diagnosed in her 50โs. While I didnโt grow up being afraid of the disease, I was far more aware of it than were …
Permanent link to this article: https://inheritedcancer.net/spotlightnls2018/
Permanent link to this article: https://inheritedcancer.net/1nls2018/
ICARE Newsletter Summer 2018
Prevention of Colorectal Cancer Among Individuals with Familial Adenomatous Polyposis (FAP)
ICARE Newsletter Summer 2018
Prevention of Colorectal Cancer Among Individuals with Familial Adenomatous Polyposis (FAP)
Through a randomized trial, patients with FAP were treated with sulindac and erlotinib versus placebo for 6 months. Results of the study showed that those treated with sulindac and erlotinib had 70% fewer polyps than those in the placebo group. The lower number of polyps was seen in both those with an intact colorectum and …
Permanent link to this article: https://inheritedcancer.net/9nls2018/
ICARE Newsletter Summer 2018
NTHL1: A New Gene for Inherited Colorectal Cancers
ICARE Newsletter Summer 2018
NTHL1: A New Gene for Inherited Colorectal Cancers
In a study of 51 individuals with multiple colon polyps drawn from 48 families, genetic testing through whole-exome sequencing identified 7 individuals (from 3 unrelated families) to have a mutation in both copies of their NTHL1 gene, and pedigree structure was consistent with autosomal recessive inheritance.1 All these individuals had colorectal cancer and a large …
Permanent link to this article: https://inheritedcancer.net/6nls2018/
ICARE Newsletter Summer 2018
Updates to NCCN Genetic/Familial High-Risk Assessment: Colorectal Guidelines
ICARE Newsletter Summer 2018
Updates to NCCN Genetic/Familial High-Risk Assessment: Colorectal Guidelines
For Individuals with Lynch Syndrome: Surveillance for gastric and small bowel cancer now indicates there is no clear data to support this, but surveillance can be performed every 3-5 years starting at age 40 Lack of evidence to make a recommendation for pancreatic or prostate cancer screening, beyond those already recommended through other NCCN Guideline …
Permanent link to this article: https://inheritedcancer.net/2nls2018/
ICARE Newsletter Summer 2018
Another PARP-Inhibitor Trial Among BRCA Carriers with Advanced Breast Cancer
ICARE Newsletter Summer 2018
Another PARP-Inhibitor Trial Among BRCA Carriers with Advanced Breast Cancer
In a Phase 3 clinical trial among BRCA carriers with advanced breast cancer, an oral PARP Inhibitor (talazoparib) was compared to standard chemotherapy. Among those who received the PARP inhibitor, risk of disease progression or death was 46% lower, and the response rate was double. Furthermore, the side effect profile, quality-of-life measures, and breast cancer …
Permanent link to this article: https://inheritedcancer.net/8nls2018/
ICARE Newsletter Summer 2018
Inherited Leukemias: The Importance of TP53/Li-Fraumeni Syndrome and Other Genes
ICARE Newsletter Summer 2018
Inherited Leukemias: The Importance of TP53/Li-Fraumeni Syndrome and Other Genes
It has long been established that the risk for developing leukemia in childhood is high among individuals with Li-Fraumeni Syndrome; however, better understanding the characteristics of leukemia among these individuals is important to guide treatment approaches. In a study of children with Acute Lymphocytic Leukemia (ALL), those with a germline TP53 mutation (compared to those …
Permanent link to this article: https://inheritedcancer.net/11nls2018/
ICARE Newsletter Summer 2018
Differences in Breast Cancer Risks Among Women with Lynch Syndrome
ICARE Newsletter Summer 2018
Differences in Breast Cancer Risks Among Women with Lynch Syndrome
Breast cancer risks were recently reported among a sample of 423 women with mutations in one of the Lynch syndrome genes (MLH1, MSH2, MSH6, or PMS2).1 Results indicated that breast cancer risks were substantially higher among those with MSH6 and PMS2 mutations, compared to MLH1 and MSH2 mutations. In fact, breast cancer risk to age …
Permanent link to this article: https://inheritedcancer.net/3nls2018/
ICARE Newsletter Summer 2018
New Data to Suggest Additional Genes Associated with Breast and Ovarian Cancer
ICARE Newsletter Summer 2018
New Data to Suggest Additional Genes Associated with Breast and Ovarian Cancer
A recent study reported on cancer risks among over 10,000 cancer patients across the United States who had genetic testing. Findings suggest breast cancer risks were associated with ATM, CHEK2, and PALB2, as expected; but an association was also found with MSH6 (in line with other recently published data, as outlined in another article in …
Permanent link to this article: https://inheritedcancer.net/7nls2018/
ICARE Newsletter Summer 2018
Refining Cancer Risks Among Individuals with Lynch Syndrome
ICARE Newsletter Summer 2018
Refining Cancer Risks Among Individuals with Lynch Syndrome
Over the past year, multiple studies have refined risks and types of cancer among individuals with Lynch syndrome. Through a Scandinavian study, risks for 13 types of cancer (with colorectal cancers being excluded), were reported to be elevated with differences related to gender, age, and the gene in which mutation was present. Incidence rates of …
Permanent link to this article: https://inheritedcancer.net/5nls2018/
ICARE Newsletter Summer 2018
Ask the Expert
ICARE Newsletter Summer 2018
Ask the Expert
The following question was addressed by Ronald D. Alvarez, MD, MBA who is Professor, Chairman, and Clinical Service Chief of the Department of Obstetrics and Gynecology at Vanderbilt University Medical Center in Nashville, Tennessee. Dr. Alvarez has been the recipient of several National Cancer Institute (NCI) and other industry funded grants in support of his …
Permanent link to this article: https://inheritedcancer.net/10nls2018/
ICARE Newsletter Winter 2018
Community Spotlight
ICARE Newsletter Winter 2018
Community Spotlight
A cancer diagnosis is a life-changing event for every patient and their extended family. However, how we respond to this diagnosis are as individual as our very existence as evidenced by our looks and personalities. Following my diagnosis of stage 4 prostate cancer in 2014 at age 54 which had spread to my bones, I …
Permanent link to this article: https://inheritedcancer.net/spotlightnlw2018/
ICARE Newsletter Winter 2018
Advances in the Understanding of Inherited Prostate Cancer
ICARE Newsletter Winter 2018
Advances in the Understanding of Inherited Prostate Cancer
Findings through a recent study reported that inherited cancer gene mutations were present in 8.2% of those with advanced or metastatic prostate cancer, which provides additional support to include this group of men in broader testing, particularly as targeted treatments based on inherited gene mutations becomes increasingly available.1 Another recent study suggested that those with …
Permanent link to this article: https://inheritedcancer.net/10nlw2018/
ICARE Newsletter Winter 2018
The Role of โNon-Truncatingโ Mutations in RAD51D on Ovarian Cancer Risk
ICARE Newsletter Winter 2018
The Role of โNon-Truncatingโ Mutations in RAD51D on Ovarian Cancer Risk
As testing has broadened to include newer inherited cancer genes, studies have suggested that mutations which shorten the protein (โtruncating mutationsโ) in the RAD51D gene are associated with ovarian cancer. However, a recent study examined ovarian cancer risks for a โnon-truncatingโ change (a single base pair within the gene is changed which is called a …
Permanent link to this article: https://inheritedcancer.net/3nlw2018/
ICARE Newsletter Winter 2018
Updates to NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines
ICARE Newsletter Winter 2018
Updates to NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines
(Version 1.2018, posted Oct. 3, 2017) Metastatic prostate cancer was added as an indication for evaluation and testing for the BRCA1 and BRCA2 genes Among BRCA1, BRCA2, TP53 and PTEN carriers, women between ages 25-29 may consider having an annual mammogram with consideration of tomosynthesis if a breast MRI is not available. Among female BRCA2 …
Permanent link to this article: https://inheritedcancer.net/1nlw2018/
ICARE Newsletter Winter 2018
Getting Closer to Detecting Cancers Early Through a Blood Test?
ICARE Newsletter Winter 2018
Getting Closer to Detecting Cancers Early Through a Blood Test?
A recent study reported on a single blood test, named โCancerSEEKโ, which can screen for 8 common types of cancer (ovarian, liver, stomach, pancreas, esophagus, colorectal, lung, and breast) and may help to identify the location at which the cancer started. This test evaluated the blood from over 1000 patients with Stage 1 to 3 …
Permanent link to this article: https://inheritedcancer.net/2nlw2018/
ICARE Newsletter Winter 2018
Advances in New Treatments for Individuals with Lynch Syndrome
ICARE Newsletter Winter 2018
Advances in New Treatments for Individuals with Lynch Syndrome
A recently published phase II clinical trial investigated the use of a new class of drugs (called PD-1 Inhibitors) in DNA mismatch repair-deficient/ microsatellite instability-high colorectal tumors (which are features seen in the majority of colorectal tumors from individuals with Lynch Syndrome) among patients with metastatic disease.1 Investigators found patients who received two PD-1 Inhibitors …
Permanent link to this article: https://inheritedcancer.net/7nlw2018/
ICARE Newsletter Winter 2018
Refining Risks and Outcomes of Breast Cancer in BRCA Carriers
ICARE Newsletter Winter 2018
Refining Risks and Outcomes of Breast Cancer in BRCA Carriers
In an effort to further study breast cancer risks among BRCA carriers, a recently published study compared breast cancer risks among those with and without a close family member (first-degree relative) with breast cancer.1 Findings showed that risk for breast cancer by age 80 was 60.8% in BRCA1 carriers and 63.1% among BRCA2 carriers, with …
Permanent link to this article: https://inheritedcancer.net/4nlw2018/
ICARE Newsletter Winter 2018
FDA Approval of PARP Inhibitor (Lynparza) for Treatment of Advanced Breast Cancer
ICARE Newsletter Winter 2018
FDA Approval of PARP Inhibitor (Lynparza) for Treatment of Advanced Breast Cancer
On January 12, 2018, the FDA approved the first PARP Inhibitor (Lynparza) for treatment in patients with advanced breast cancer due to inherited BRCA mutations.1 This drug is already approved for certain BRCA carriers for advanced ovarian cancer. PARP inhibitors were originally developed to target the specific pathway through which cancer develops among those with …
Permanent link to this article: https://inheritedcancer.net/6nlw2018/
ICARE Newsletter Winter 2018
Ask the Expert
ICARE Newsletter Winter 2018
Ask the Expert
The following question was addressed by Dr. Ingrid Meszoely is a breast surgeon and Clinical Director of the Vanderbilt Breast Center at One Hundred Oaks. She leads a high-risk clinic, through which she and her team of nurse practitioners manage patients with inherited breast cancer predisposition. Her research interests include both clinical and translational breast …
Permanent link to this article: https://inheritedcancer.net/8nlw2018/
ICARE Newsletter Winter 2018
Study Suggests Inherited Cancer Genes Are Important in Pancreatic Cancer
ICARE Newsletter Winter 2018
Study Suggests Inherited Cancer Genes Are Important in Pancreatic Cancer
In a recent study which included over 800 patients with pancreatic ductal cancer, inherited cancer gene mutations were found in a much higher proportion than expected. Almost 5% of these patients had mutations identified in inherited cancer genes, the majority of which were in genes thought to be associated with pancreatic cancer (including BRCA2, ATM, …
Permanent link to this article: https://inheritedcancer.net/9nlw2018/
ICARE Newsletter Winter 2018
Advances in Cancer Screening Among Li-Fraumeni Syndrome Patients
ICARE Newsletter Winter 2018
Advances in Cancer Screening Among Li-Fraumeni Syndrome Patients
Several research groups from around the world that have conducted cancer screening among patients with Li-Fraumeni syndrome and a germline TP53 mutation have recently reported on their observations. Specifically, the National Cancer Institute group demonstrated that screening inclusive of rapid total body MRI detected cancers at an early stage,1 similar to findings published through other …
Permanent link to this article: https://inheritedcancer.net/5nlw2018/
ICARE Newsletter Summer 2017
Ask the Expert
ICARE Newsletter Summer 2017
Ask the Expert
The following question was addressed by Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at the Womenโs College Research Institute in Toronto, Canada. Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Q. In women with a BRCA mutation and …
Permanent link to this article: https://inheritedcancer.net/6nls2017/
ICARE Newsletter Summer 2017
Emerging FDA Approvals of Immunotherapy Among Patients With Metastatic MSI-H Cancers
ICARE Newsletter Summer 2017
Emerging FDA Approvals of Immunotherapy Among Patients With Metastatic MSI-H Cancers
Over the last few years, immunotherapy has emerged as an exciting new class of drugs. As early as 2015, immunotherapy through PD-1 Inhibitors among patients with MSI-H colorectal cancers was shown to be of potential benefit.1 As many individuals with Lynch Syndrome have cancers that are MSI-H and mismatch repair deficient, this class of drugs …
Permanent link to this article: https://inheritedcancer.net/5nls2017/
ICARE Newsletter Summer 2017
Breast and Ovarian Cancer Risks Among BRCA Carriers Followed Over Time
ICARE Newsletter Summer 2017
Breast and Ovarian Cancer Risks Among BRCA Carriers Followed Over Time
Findings from an international study of over 6000 women with a BRCA1 mutation and almost 4000 women with a BRCA2 mutation followed for an average of 5 years were recently published.1 Results showed the risk of breast cancer by age 80 was ~70% for both BRCA1 and BRCA2 carriers. Rates of breast cancer increased until …
Permanent link to this article: https://inheritedcancer.net/1nls2017/
ICARE Newsletter Summer 2017
Community Spotlight
ICARE Newsletter Summer 2017
Community Spotlight
After a long rainy summer filled with doctor visits, I was finally diagnosed with triple-negative inflammatory breast cancer (TN IBC) at the age of 49. I completed treatment in June 2008 and was grateful to have a new phase to my vocabulary โ NED, โno evidence of diseaseโ. Since there was no cancer history in my …
Permanent link to this article: https://inheritedcancer.net/spotlightnls2017/
ICARE Newsletter Summer 2017
New Results of a PARP Inhibitor Study Among BRCA Carriers with Metastatic Breast Cancer
ICARE Newsletter Summer 2017
New Results of a PARP Inhibitor Study Among BRCA Carriers with Metastatic Breast Cancer
Over the last decade, a new class of drugs called โPARP Inhibitorsโ has been evaluated as a form of targeted treatment among BRCA carriers. Results were recently reported from a Phase 3 clinical trial among BRCA carriers with HER2-negative metastatic breast cancer who received two or less prior chemotherapy regimens for their metastatic disease. Study …
Permanent link to this article: https://inheritedcancer.net/4nls2017/
ICARE Newsletter Summer 2017
What Are the Benefits of Adding a Mammogram to MRI for Breast Cancer Screening Among Women with BRCA Mutations?
ICARE Newsletter Summer 2017
What Are the Benefits of Adding a Mammogram to MRI for Breast Cancer Screening Among Women with BRCA Mutations?
Recently, researchers evaluated the benefit of adding a mammogram to MRI for breast cancer screening among ~2000 women with a BRCA1 or BRCA2 mutation. Results indicated that the addition of mammography to MRI did not substantially raise the chance of detecting breast cancer in the overall group. However, one-third of breast cancer cases diagnosed among …
Permanent link to this article: https://inheritedcancer.net/7nls2017/
ICARE Newsletter Summer 2017
What Are New and Subsequent Cancer Risks Among Patients with Li-Fraumeni Syndrome?
ICARE Newsletter Summer 2017
What Are New and Subsequent Cancer Risks Among Patients with Li-Fraumeni Syndrome?
Although individuals with Li-Fraumeni Syndrome (LFS), due to mutations in the TP53 gene, have a very high lifetime risk of cancer, risks of initial and subsequent cancers are not well defined. Through a group of patients with the classic form of LFS, researchers at the National Cancer Institute estimated their cancer risks. They evaluated a …
Permanent link to this article: https://inheritedcancer.net/3nls2017/
Permanent link to this article: https://inheritedcancer.net/2nls2017/
ICARE Newsletter Winter 2017
Community Spotlight
ICARE Newsletter Winter 2017
Community Spotlight
On my 43rd birthday I was diagnosed with an advanced stage breast cancer. Although my BRCA1 and BRCA2 results were surprisingly negative, I was certain there must be a genetic component to my breast cancer since I was diagnosed at a fairly young age. I remained in contact with my geneticist, Dr. Georgia Wiesner, and …
Permanent link to this article: https://inheritedcancer.net/spotlightnlw2017/
ICARE Newsletter Winter 2017
Newly Approved PARP-Inhibitor (Rucaparib) to Treat BRCA Carriers with Ovarian Cancer
ICARE Newsletter Winter 2017
Newly Approved PARP-Inhibitor (Rucaparib) to Treat BRCA Carriers with Ovarian Cancer
The FDA just approved another PARP inhibitor, rucaparib, for BRCA carriers with ovarian cancer who have already been treated with two or more chemotherapies. Among those with BRCA-mutant ovarian cancers, 54% had a partial or complete response to the drug with a median duration response of 9.2 months. The agency also approved a companion diagnostic …
Permanent link to this article: https://inheritedcancer.net/6nlw2017/
ICARE Newsletter Winter 2017
Characterizing Breast Cancers That Develop Among Women with a CHEK2 Mutation
ICARE Newsletter Winter 2017
Characterizing Breast Cancers That Develop Among Women with a CHEK2 Mutation
With increasing use of multi-gene panel tests, one of the genes in which mutations are frequently detected among breast cancer patients and others is the CHEK2 gene. This gene has been shown to have a 2-3 fold excess risk for breast cancer. There are many CHEK2 mutations that have been identified that generally fall into …
Permanent link to this article: https://inheritedcancer.net/8nlw2017/
ICARE Newsletter Winter 2017
New Study Suggesting BRCA1/2 and ATM Are Associated with Aggressive Prostate Cancer
ICARE Newsletter Winter 2017
New Study Suggesting BRCA1/2 and ATM Are Associated with Aggressive Prostate Cancer
Among 799 patients with prostate cancer, the rate of BRCA1/2 mutations was much higher among those who passed away of prostate cancer (6.07%) compared to those with low risk disease (1.44%).1 Among the group that died of prostate cancer, those with BRCA1/2 or ATM mutations passed away at an earlier age and had a shorter …
Permanent link to this article: https://inheritedcancer.net/3nlw2017/
ICARE Newsletter Winter 2017
NCCN Guidelines Version 1.2017: Genetic/Familial High-Risk Assessment: Breast and Ovarian
ICARE Newsletter Winter 2017
NCCN Guidelines Version 1.2017: Genetic/Familial High-Risk Assessment: Breast and Ovarian
Additional guidance pertaining to cancer risk management was provided in the most recent version of the NCCN Guidelines for inherited breast and ovarian cancer. These guidelines now include an expanded table outlining cancer risks and management for each gene, taking into account the age at initiation of each risk management modality as well as footnotes …
Permanent link to this article: https://inheritedcancer.net/1nlw2017/
ICARE Newsletter Winter 2017
A Newly Identified Inherited Colon Cancer Gene: FAN1
ICARE Newsletter Winter 2017
A Newly Identified Inherited Colon Cancer Gene: FAN1
There continues to be rapid advances in identifying new genes involved in inherited cancer risk. An example of yet another recently identified gene is FAN1, in which a nonsense variant (i.e. the premature change or loss of a protein) was identified following exome sequencing in 3 individuals from a family who met clinical criteria for …
Permanent link to this article: https://inheritedcancer.net/4nlw2017/
ICARE Newsletter Winter 2017
Ask the Expert
ICARE Newsletter Winter 2017
Ask the Expert
The following question was addressed by Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at the Womenโs College Research Institute in Toronto, Canada. Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Q. Does salpingo-oophorectomy reduce the risk of breast …
Permanent link to this article: https://inheritedcancer.net/7nlw2017/
ICARE Newsletter Winter 2017
The Potential Promise of Immunotherapy Targeted to Those with Bi-Allelic Mutations in Lynch Syndrome Genes
ICARE Newsletter Winter 2017
The Potential Promise of Immunotherapy Targeted to Those with Bi-Allelic Mutations in Lynch Syndrome Genes
People with Lynch Syndrome have a non-working Lynch gene (โmutationโ), while the other copy of that gene is normal (recognizing that all of these genes come in pairs, with one member of the pair coming from each parent). Over the last few years, there has been an increased realization that some individuals have a mutation …
Permanent link to this article: https://inheritedcancer.net/2nlw2017/
ICARE Newsletter Winter 2017
How Does Having a Mother with Breast Cancer and a BRCA Mutation Affect Adolescent Girls?
ICARE Newsletter Winter 2017
How Does Having a Mother with Breast Cancer and a BRCA Mutation Affect Adolescent Girls?
A recent study compared psychosocial adjustment and risk perception among 11 to 19 year old daughters of women with breast cancer, comparing those with a BRCA mutation versus those without.1 The overall findings from the study were reassuring, suggesting that adolescent girls from BRCA-positive families had higher self-esteem and similar psychosocial adjustment compared to their …
Permanent link to this article: https://inheritedcancer.net/5nlw2017/
ICARE Newsletter Summer 2016
Cancer Chemoprevention in Individuals with Familial Adenomatous Polyposis (FAP)
ICARE Newsletter Summer 2016
Cancer Chemoprevention in Individuals with Familial Adenomatous Polyposis (FAP)
Prior research has demonstrated that NSAIDs significantly reduce colonic and rectal polyp burden among individuals with FAP although their impact on outcomes remains to be determined.1,2 Recent data extended these results to the small intestine through completion of a randomized clinical trial among patients with FAP which demonstrated that use of sulindac and erlotinib compared …
Permanent link to this article: https://inheritedcancer.net/7nls2016/
ICARE Newsletter Summer 2016
Practice Guideline Updates for NCCN Genetic/Familial High-Risk Assessment
ICARE Newsletter Summer 2016
Practice Guideline Updates for NCCN Genetic/Familial High-Risk Assessment
The National Comprehensive Cancer Network (NCCN) is a network of oncology healthcare providers who work together to develop best practice guidelines for the delivery of cancer care. Given the increasing use of testing for mutations in several inherited cancer genes at one time (called โmulti-gene panel testingโ), the Breast/Ovarian and Colorectal Panels sought to provide …
Permanent link to this article: https://inheritedcancer.net/1nls2016/
ICARE Newsletter Summer 2016
What Are the Endometrial Cancer Risks Among BRCA Carriers?
ICARE Newsletter Summer 2016
What Are the Endometrial Cancer Risks Among BRCA Carriers?
Although BRCA mutations confer increased risk for ovarian, fallopian tube, and primary peritoneal cancer, there have been limited and conflicting risks reported for endometrial cancer. Consequently, current practice guidelines only recommend the removal of the fallopian tubes and ovaries as a risk-reducing option for BRCA carriers.1 Specifically, through a prospective study of 4500 women with …
Permanent link to this article: https://inheritedcancer.net/9nls2016/
ICARE Newsletter Summer 2016
CHEK2 *1100delC Mutation Carriers: Breast Cancer Risk by Age and Tumor Type and Other Associated Cancer Risks
ICARE Newsletter Summer 2016
CHEK2 *1100delC Mutation Carriers: Breast Cancer Risk by Age and Tumor Type and Other Associated Cancer Risks
The CHEK2 *1100delC mutation is the most common โtruncatingโ mutation (causing a shortened protein) in the CHEK2 gene among Europeans, with lifetime breast cancer risk in the range of 20-30% among female carriers. Results of data pooled from over 30 studies which included 40,000 breast cancer cases and 40,000 controls, showed that estrogen receptor (ER) …
Permanent link to this article: https://inheritedcancer.net/6nls2016/
ICARE Newsletter Summer 2016
Practice Guideline Updates for NCCN Genetic/Familial High-Risk Assessment
ICARE Newsletter Summer 2016
Practice Guideline Updates for NCCN Genetic/Familial High-Risk Assessment
The National Comprehensive Cancer Network (NCCN) is a network of oncology healthcare providers who work together to develop best practice guidelines for the delivery of cancer care. Given the increasing use of testing for mutations in several inherited cancer genes at one time (called โmulti-gene panel testingโ), the Breast/Ovarian and Colorectal Panels sought to provide …
Permanent link to this article: https://inheritedcancer.net/2nls2016/
ICARE Newsletter Summer 2016
Risk of Second Cancers Among Those with PTEN Mutations
ICARE Newsletter Summer 2016
Risk of Second Cancers Among Those with PTEN Mutations
A recently published study to evaluate the risk of second cancers among PTEN mutation carriers showed that women with breast cancer had a 10-year second breast cancer cumulative risk of almost 30%. Overall, the risk of second primary cancers was almost 8-fold that of the general population, primarily due to the higher risks of cancer …
Permanent link to this article: https://inheritedcancer.net/8nls2016/
ICARE Newsletter Summer 2016
Ask the Expert
ICARE Newsletter Summer 2016
Ask the Expert
The following question was addressed by Dr. Christine Laronga at the Moffitt Cancer Center: Q. How should bone health be monitored in women with a BRCA mutation after removal of the ovaries (i.e., risk-reducing salpingo-oophorectomy (RRSO))? A. Women with a BRCA mutation have a substantially high risk to develop ovarian cancer in their lifetime, yet …
Permanent link to this article: https://inheritedcancer.net/10nls2016/
ICARE Newsletter Summer 2016
Surveillance Among Individuals with Li-Fraumeni Syndrome (LFS): An 11 Year Follow-Up Study
ICARE Newsletter Summer 2016
Surveillance Among Individuals with Li-Fraumeni Syndrome (LFS): An 11 Year Follow-Up Study
Results from the original screening protocol for LFS1 were recently updated following collection of 11 years of follow-up data.2 Through this study, 89 patients with LFS were given the option of a clinical surveillance protocol consisting of a physical examination as well as frequent biochemical and imaging studies. Forty asymptomatic tumors were detected in 32% …
Permanent link to this article: https://inheritedcancer.net/4nls2016/
ICARE Newsletter Summer 2016
Inherited Cancer Genes and Metastatic Prostate Cancer
ICARE Newsletter Summer 2016
Inherited Cancer Genes and Metastatic Prostate Cancer
Several prior studies have suggested that men with a BRCA mutation (primarily BRCA2) tend to develop an aggressive form of prostate cancer that is more likely to metastasize. These findings were recently extended through a new study published in the New England Journal of Medicine.1 In this study, almost 700 men with metastatic prostate cancer, …
Permanent link to this article: https://inheritedcancer.net/5nls2016/
ICARE Newsletter Summer 2016
Community Spotlight
ICARE Newsletter Summer 2016
Community Spotlight
When I was diagnosed with cancer the first time at age 38, my sister (a breast cancer survivor since the age of 29) was positive we had a BRCA gene mutation. However, after we both had genetic testing done in 2006 the results showed we didnโt. Doctors said they were surprised we did not have a mutation in one of …
Permanent link to this article: https://inheritedcancer.net/spotlightnls2016/
ICARE Newsletter Summer 2016
An Approach to Making Risk Management Recommendations for Newer Inherited Cancer Genes
ICARE Newsletter Summer 2016
An Approach to Making Risk Management Recommendations for Newer Inherited Cancer Genes
A recent article sought to develop an approach to cancer risk management among individuals with mutations in newer inherited cancer genes, many of which result in a moderate (rather than โhighโ) cancer risk. Overall, the investigators suggest a framework that takes the age-specific, lifetime, and absolute cancer risks into account for inherited cancer genes where …
Permanent link to this article: https://inheritedcancer.net/3nls2016/
ICARE Newsletter Winter 2016
Improving Our Understanding of Cancer Risks Among Individuals with Li-Fraumeni Syndrome
ICARE Newsletter Winter 2016
Improving Our Understanding of Cancer Risks Among Individuals with Li-Fraumeni Syndrome
A recent study from France included over 400 patients with Li-Fraumeni Syndrome (all of whom had an inherited TP53 gene mutation). Cancer types among children and adults differed, with the main cancer types among children being osteosarcomas, adrenocortical carcinomas, central nervous system (CNS) tumors and soft tissue sarcomas; whereas among adults, the main cancer types …
Permanent link to this article: https://inheritedcancer.net/5nlw2016/
ICARE Newsletter Winter 2016
How Much Does Age at First Breast Cancer Affect the Risk of Contralateral Breast Cancer Risk in BRCA Carriers?
ICARE Newsletter Winter 2016
How Much Does Age at First Breast Cancer Affect the Risk of Contralateral Breast Cancer Risk in BRCA Carriers?
A recently published study of Dutch patients (including 200 BRCA1 carriers, 71 BRCA2 carriers, and 6023 non-carriers) showed that the contralateral breast cancer (breast cancer in the opposite breast) risks at 10 years was 21.1% for BRCA1, 10.8% for BRCA2, and 5.1% for non-carriers. Among BRCA mutation carriers, it was important to take age at …
Permanent link to this article: https://inheritedcancer.net/3nlw2016/
ICARE Newsletter Winter 2016
Ask the Expert
ICARE Newsletter Winter 2016
Ask the Expert
The following question was addressed by Dr. Christine Laronga at the Moffitt Cancer Center: Q. As a BRCA carrier, is it reasonable for me to consider nipple-sparing mastectomy (compared to total mastectomy) to reduce my future risks of breast cancer? A. One strategy to manage the high (60-70%) lifetime breast cancer risk among women with …
Permanent link to this article: https://inheritedcancer.net/6nlw2016/
ICARE Newsletter Winter 2016
Community Spotlight
ICARE Newsletter Winter 2016
Community Spotlight
I was first diagnosed with breast cancer when I was 56 years old. Because of my strong family history of breast cancer, I was referred for genetic counseling and had BRCA testing at that time. Recently, I was diagnosed with breast cancer again. When I went to see my surgeon, she advised me to have more genetic …
Permanent link to this article: https://inheritedcancer.net/spotlightnlw2016/
ICARE Newsletter Winter 2016
Potential Use of PARP-Inhibitors Among Men with Prostate Cancer Who Carry a Mutation in BRCA or Other DNA-Repair Gene
ICARE Newsletter Winter 2016
Potential Use of PARP-Inhibitors Among Men with Prostate Cancer Who Carry a Mutation in BRCA or Other DNA-Repair Gene
A recent study published in the New England Journal of Medicine suggests that PARP-Inhibitors may be of potential use in men who are no longer responding to standard treatments and carry either somatic (i.e., tumor) and/or germline (inherited) mutations in DNA-repair genes (i.e., BRCA1/2, ATM, Fanconi Anemia genes and CHEK2).1 Of 49 men with prostate …
Permanent link to this article: https://inheritedcancer.net/4nlw2016/
ICARE Newsletter Winter 2016
The Importance of Sharing Genetic Test Results with Family Members
ICARE Newsletter Winter 2016
The Importance of Sharing Genetic Test Results with Family Members
Once an individual has had genetic testing for inherited cancer predisposition this information could help their close family members. For example, when a BRCA mutation or a mutation in another inherited cancer gene is found, it is important for close family members (with or without a diagnosis of cancer) to know so they too can …
Permanent link to this article: https://inheritedcancer.net/1nlw2016/
ICARE Newsletter Winter 2016
What Is the Risk for Ovarian Cancer Among Women with Mutations in Newer Ovarian Cancer Genes?
ICARE Newsletter Winter 2016
What Is the Risk for Ovarian Cancer Among Women with Mutations in Newer Ovarian Cancer Genes?
The most common form of inherited ovarian cancer is due to mutations in the BRCA1 and BRCA2 genes, which are present in 10-15% of women with ovarian cancer and lead to an ovarian cancer risk of up to 44% and 27%, respectively. Another set of genes known to raise ovarian cancer risks are the mismatch …
Permanent link to this article: https://inheritedcancer.net/2nlw2016/
ICARE Newsletter Winter 2016
More Information About the Inherited Component of Pancreatic Cancer
ICARE Newsletter Winter 2016
More Information About the Inherited Component of Pancreatic Cancer
Although pancreatic cancer is one of the cancer types seen among individuals with mutations in inherited cancer genes (including BRCA2 and BRCA1), the proportion of individuals with pancreatic cancer who have an inherited cause has remained uncertain. To further clarify the role of BRCA1 and BRCA2 (BRCA), over 300 patients with pancreatic cancer were tested …
Permanent link to this article: https://inheritedcancer.net/7nlw2016/
ICARE Newsletter Summer 2015
The Rapid Pace of Discovering More Inherited Cancer Genes Continues
ICARE Newsletter Summer 2015
The Rapid Pace of Discovering More Inherited Cancer Genes Continues
Over the last few months, a number of additional genes associated with inherited cancer predisposition have been identified. A few of these genes include: 1) the RECQL gene which appears to be another rare gene involved in inherited breast cancer1; 2) the SMAD9 gene associated with hamartomatous polyposis and ganglioneuromas of the intestinal tract2; 3) …
Permanent link to this article: https://inheritedcancer.net/2nls2015/
ICARE Newsletter Summer 2015
Location and Type of BRCA1/2 Mutation May Impact Breast and Ovarian Cancer Risks
ICARE Newsletter Summer 2015
Location and Type of BRCA1/2 Mutation May Impact Breast and Ovarian Cancer Risks
A study of almost 20,000 BRCA1 carriers and 12,000 BRCA2 carriers demonstrated differences in breast and ovarian cancer risks depending on the location and type of mutation. Although all regions are associated with increased risk for breast and ovarian cancers among BRCA1/2 carriers, there were specific regions that were associated with even higher cancer risks. …
Permanent link to this article: https://inheritedcancer.net/4nls2015/
ICARE Newsletter Summer 2015
Advances in Preventive and Treatment Approaches for Individuals with Lynch Syndrome
ICARE Newsletter Summer 2015
Advances in Preventive and Treatment Approaches for Individuals with Lynch Syndrome
A study of over 1800 individuals with a mutation in one of the Lynch Syndrome genes was recently completed to assess whether aspirin and ibuprofen use may reduce colon cancer risk. Results showed that in those who took aspirin or ibuprofen for between 1 month and 4.9 years, the colon cancer risks were lower than …
Permanent link to this article: https://inheritedcancer.net/6nls2015/
ICARE Newsletter Summer 2015
Breast Cancer Risks and Outcomes Among Women with a PALB2 Mutation
ICARE Newsletter Summer 2015
Breast Cancer Risks and Outcomes Among Women with a PALB2 Mutation
Through a recent study of over 12,000 Polish women with breast cancer, PALB2 mutations were detected in almost 1%. In this study, about one third of those with a PALB2 mutation had triple negative (lacking estrogen, progesterone and HER2 receptors) breast cancer and the average age at breast cancer diagnosis was 53.3 years. Breast tumors …
Permanent link to this article: https://inheritedcancer.net/3nls2015/
Permanent link to this article: https://inheritedcancer.net/1nls2015/
ICARE Newsletter Summer 2015
Ask the Expert
ICARE Newsletter Summer 2015
Ask the Expert
The following question was addressed to Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at Womenโs College Research Institute in Toronto, Canada. Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Over the course of his career, he has profoundly shaped …
Permanent link to this article: https://inheritedcancer.net/5nls2015/
ICARE Newsletter Winter 2015
Highlights of the 2014 National Comprehensive Cancer Network (NCCN) Update
ICARE Newsletter Winter 2015
Highlights of the 2014 National Comprehensive Cancer Network (NCCN) Update
Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines For breast cancer screening in BRCA carriers, yearly MRI is recommended starting at age 25; mammograms may be considered in instances where MRI is unavailable or individualized based on earliest age of onset in the family. From age 30-75, annual mammogram and breast MRI is recommended. Above age …
Permanent link to this article: https://inheritedcancer.net/5nlw2015/
ICARE Newsletter Winter 2015
Highlights of the 2014 National Comprehensive Cancer Network (NCCN) Update
ICARE Newsletter Winter 2015
Highlights of the 2014 National Comprehensive Cancer Network (NCCN) Update
Genetic/Familial High-Risk Assessment: Colorectal Guidelines Recommendation that tumors from newly diagnosed colorectal cancer patients be screened for Lynch syndrome (called โUniversal Tumor Screeningโ). A new algorithm was created for Routine Tumor Testing Criteria for Lynch Syndrome Surveillance/Management recommendations were refined by gene for the various Lynch Syndrome genes. Management recommendations were refined for other inherited …
Permanent link to this article: https://inheritedcancer.net/6nlw2015/
ICARE Newsletter Winter 2015
PALB2: A Third Important Gene for Inherited Breast Cancer
ICARE Newsletter Winter 2015
PALB2: A Third Important Gene for Inherited Breast Cancer
Following the publication of an important article in the New England Journal of Medicine (NEJM) in August 2014, germline PALB2 gene mutations were confirmed as the third most important gene for inherited breast cancer, following BRCA1 and BRCA2.1 PALB2 stands for โpartner and localizer of BRCA2โ and is located on chromosome 16. Studies suggest that PALB2 mutations …
Permanent link to this article: https://inheritedcancer.net/1nlw2015/
ICARE Newsletter Winter 2015
The First PARP-Inhibitor to Be Approved for Clinical Use in BRCA Carriers
ICARE Newsletter Winter 2015
The First PARP-Inhibitor to Be Approved for Clinical Use in BRCA Carriers
More frequently, cancer drugs are being developed to treat tumors based on their molecular make-up. PARP inhibitors are the first class of drugs specifically developed to treat BRCA-related tumors through targeting the DNA repair pathway. The PARP Inhibitors target this pathway and cause cancer cells to die while healthy cells are spared. Although PARP inhibitors …
Permanent link to this article: https://inheritedcancer.net/2nlw2015/
ICARE Newsletter Winter 2015
Discovery of New Colorectal Cancer Genes
ICARE Newsletter Winter 2015
Discovery of New Colorectal Cancer Genes
New inherited cancer genes continue to be discovered with the exciting advances made possible through next-generation sequencing technologies. Recent studies identified that the POL genes predispose to inherited colorectal cancer.1,2,3 In one study, Niemenen and colleagues studied a four-generation family with Lynch Syndrome with no evidence of mismatch repair deficiency.2 Through various means (including genetic …
Permanent link to this article: https://inheritedcancer.net/4nlw2015/
ICARE Newsletter Winter 2015
Ask the Expert
ICARE Newsletter Winter 2015
Ask the Expert
The following question was addressed to Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at Womenโs College Research Institute in Toronto, Canada. Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Over the course of his career, he has profoundly shaped …
Permanent link to this article: https://inheritedcancer.net/3nlw2015/
ICARE Newsletter Summer 2014
Is Breast Cancer Risk Affected by Timing of Oral Contraceptives in BRCA1 Carriers?
ICARE Newsletter Summer 2014
Is Breast Cancer Risk Affected by Timing of Oral Contraceptives in BRCA1 Carriers?
Although oral contraceptives (OC) reduce the risk of ovarian cancer in BRCA carriers,1 it is possible that they may raise breast cancer risk. Thus it is important to understand whether age at OC use is a factor when determining impact on breast cancer risk. To address this question, a recent study (which included data from …
Permanent link to this article: https://inheritedcancer.net/2nls2014/
ICARE Newsletter Summer 2014
What Are Factors That Modify Cancer Risk in BRCA Carriers?
ICARE Newsletter Summer 2014
What Are Factors That Modify Cancer Risk in BRCA Carriers?
Since the discovery of the BRCA genes about two decades ago, a number of studies have reported on factors that may modify cancer risks in those who carry gene mutations. Recently, results of previously published studies were collected through a comprehensive literature review to estimate the overall effects of various risk modifiers in BRCA carriers. …
Permanent link to this article: https://inheritedcancer.net/3nls2014/
ICARE Newsletter Summer 2014
Is There a Higher Risk of Prostate Cancer in Individuals with Lynch Syndrome?
ICARE Newsletter Summer 2014
Is There a Higher Risk of Prostate Cancer in Individuals with Lynch Syndrome?
Over the last few years, there have been studies to suggest that men with Lynch Syndrome may have a higher risk for developing prostate cancer.1,2,3,4,5 The results of these studies have differed as to whether there is an association with an aggressive form of disease. For example, some studies report the risk of developing prostate …
Permanent link to this article: https://inheritedcancer.net/6nls2014/
ICARE Newsletter Summer 2014
Early Results to Suggest That PSA Screening May Help to Detect Prostate Cancer Early in Men with BRCA Mutations
ICARE Newsletter Summer 2014
Early Results to Suggest That PSA Screening May Help to Detect Prostate Cancer Early in Men with BRCA Mutations
Over the last few years, there have been a number of studies to suggest that men with BRCA mutations, particularly BRCA2, have a higher risk of developing aggressive prostate cancer. It remains uncertain whether these men might benefit from screening through the prostate-specific antigen (PSA) test. Within the last few years, PSA screening guidelines in …
Permanent link to this article: https://inheritedcancer.net/1nls2014/
ICARE Newsletter Summer 2014
Ask the Expert
ICARE Newsletter Summer 2014
Ask the Expert
The following question was addressed by Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at Womenโs College Research Institute in Toronto, Canada. Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Over the course of his career, he has profoundly shaped …
Permanent link to this article: https://inheritedcancer.net/5nls2014/
ICARE Newsletter Summer 2014
New Study to Suggest Benefits of Oophorectomy in BRCA Mutation Carriers
ICARE Newsletter Summer 2014
New Study to Suggest Benefits of Oophorectomy in BRCA Mutation Carriers
A recent study published in the Journal of Clinical Oncology reported that prophylactic oophorectomy resulted in reducing the risk of ovarian cancer by 80%, and reduced all-cause mortality by 77%.1 The authors reported results on almost 5800 women, of whom 186 developed either ovarian, fallopian tube or peritoneal cancer. Women who had bilateral oophorectomy had …
Permanent link to this article: https://inheritedcancer.net/4nls2014/
ICARE Newsletter Winter 2014
Recent Evidence to Suggest That Individuals with Germline Mutations in the PTEN gene (Which Leads to Cowden Syndrome) May Have Higher Renal Cancer Risks
ICARE Newsletter Winter 2014
Recent Evidence to Suggest That Individuals with Germline Mutations in the PTEN gene (Which Leads to Cowden Syndrome) May Have Higher Renal Cancer Risks
Cowden Syndrome is an inherited condition that leads to higher risks for breast and thyroid cancer, and possibly other cancers.1 There have been a few recent studies that suggest that this condition also puts individuals at a higher risk for kidney cancer. Specifically, Tan et al2 reported a lifetime risk of 30.6% (95% CI: 17.8-49.4) …
Permanent link to this article: https://inheritedcancer.net/3nlw2014/
ICARE Newsletter Winter 2014
Tamoxifen May Reduce Contralateral Breast Cancer Risk in BRCA Carriers
ICARE Newsletter Winter 2014
Tamoxifen May Reduce Contralateral Breast Cancer Risk in BRCA Carriers
There have been suggestions that Tamoxifen may reduce risks for contralateral breast cancer (i.e., breast cancer in the other breast) in BRCA carriers if taken after the initial breast cancer diagnosis, based mainly on retrospective studies. Only one prospective study has looked at this question, and showed that Tamoxifen may be useful in BRCA2, but …
Permanent link to this article: https://inheritedcancer.net/2nlw2014/
ICARE Newsletter Winter 2014
Ask the Expert
ICARE Newsletter Winter 2014
Ask the Expert
The following question was addressed by Dr. Laronga who is a breast surgeon based at the Moffitt Cancer Center: Q. What are the risks of breast cancer after ovarian cancer in BRCA carriers? What risk management options are recommended? A. BRCA carriers remain at a higher risk of breast cancer, even after having ovarian cancer; …
Permanent link to this article: https://inheritedcancer.net/4nlw2014/
ICARE Newsletter Winter 2014
Contralateral Mastectomy May Improve Survival in BRCA Mutation Carriers
ICARE Newsletter Winter 2014
Contralateral Mastectomy May Improve Survival in BRCA Mutation Carriers
It has been established that women who carry a germline BRCA mutation face breast cancer risks of 60-70% in their lifetime. After an initial breast cancer diagnosis, these women face a high risk for contralateral breast cancer. Some women with BRCA mutations move forward with contralateral mastectomy when they develop their first breast cancer diagnosis (as …
Permanent link to this article: https://inheritedcancer.net/1nlw2014/
ICARE Newsletter Summer 2013
Sharing BRCA Test Results with Adolescent and Young Adult ChildrenโWhat Does the Latest Research Show?
ICARE Newsletter Summer 2013
Sharing BRCA Test Results with Adolescent and Young Adult ChildrenโWhat Does the Latest Research Show?
While there are specific recommendations against BRCA testing for minors,1 guidelines are less clear about whether parents should share their own test results with their children. Because there are no recommended surveillance or risk reduction options prior to age 25 for known BRCA mutation carriers, there has been debate about balancing the benefits of sharing …
Permanent link to this article: https://inheritedcancer.net/2nls2013/
ICARE Newsletter Summer 2013
US Preventive Services Task Force (USPSTF) Guidelines for Inherited Breast and Ovarian Cancer and Implications to the Affordable Care Act (ACA)
ICARE Newsletter Summer 2013
US Preventive Services Task Force (USPSTF) Guidelines for Inherited Breast and Ovarian Cancer and Implications to the Affordable Care Act (ACA)
Recently, the USPSTF released updated draft guidelines in April 2013 (from those previously published in 2005) for inherited breast and ovarian cancer due to germline BRCA1 and BRCA2 gene mutations.1 USPSTF is comprised of primary care providers who review the available literature and issue guidelines about risk assessment, testing and management based on available evidence. …
Permanent link to this article: https://inheritedcancer.net/4nls2013/
ICARE Newsletter Summer 2013
Male BRCA Carriers Have Poorer Outcomes from Prostate Cancer
ICARE Newsletter Summer 2013
Male BRCA Carriers Have Poorer Outcomes from Prostate Cancer
Over the last few years, a number of studies have suggested that men with germline BRCA mutations (especially BRCA2) have poorer outcomes when they develop prostate cancer. In fact, a recent study of 2019 patients with prostate cancer, including 18 BRCA1 carriers, 61 BRCA2 carriers, and 1940 noncarriers indicated that germline mutations were more frequently …
Permanent link to this article: https://inheritedcancer.net/3nls2013/
ICARE Newsletter Summer 2013
Oophorectomy Following Menopause
ICARE Newsletter Summer 2013
Oophorectomy Following Menopause
Prior studies have indicated that removal of the ovaries and fallopian tubes reduces the ovarian cancer risk by ~80% and breast cancer risk by ~50%, particularly when performed pre-menopausally. However a recent case control study of 2854 pairs of women with a BRCA1 or BRCA2 mutation with or without breast cancer showed that the risk …
Permanent link to this article: https://inheritedcancer.net/5nls2013/
ICARE Newsletter Summer 2013
BRCA Testing: Supreme Court Update
ICARE Newsletter Summer 2013
BRCA Testing: Supreme Court Update
In a landmark decision regarding the patenting of human genes on Thursday June 13, 2013, the Supreme Court of the United States unanimously ruled that human genes may not be patented. The case specifically concerned the BRCA1 and BRCA2 gene patents, held by the Utah-based company, Myriad Genetics. In the ruling, Justice Clarence Thomas wrote for the …
Permanent link to this article: https://inheritedcancer.net/1nls2013/
ICARE Newsletter Summer 2013
Ask the Expert
ICARE Newsletter Summer 2013
Ask the Expert
The following question was addressed by Dr. Pal, who is a Clinical Geneticist based at the Moffitt Cancer Center: Q. Does exposure to radiation increase breast cancer risk in BRCA mutation carriers? A. A number of studies have been conducted to evaluate whether BRCA mutation carriers may be more prone to radiation-induced breast cancer than …
Permanent link to this article: https://inheritedcancer.net/6nls2013/
ICARE Newsletter Winter 2013
Ask the Expert
ICARE Newsletter Winter 2013
Ask the Expert
The following question was addressed by Dr. Lora Thompson, a Clinical Psychologist at the Moffitt Cancer Center: Q. How do I talk to family members about my genetic test results? A. The ability to share risk information with family members is a common reason why many individuals undergo genetic testing. Family members may feel appreciative …
Permanent link to this article: https://inheritedcancer.net/4nlw2013/
ICARE Newsletter Winter 2013
Points to Consider Regarding Bilateral Salpingectomy as a Risk Reduction Procedure for Ovarian Cancer
ICARE Newsletter Winter 2013
Points to Consider Regarding Bilateral Salpingectomy as a Risk Reduction Procedure for Ovarian Cancer
Over the last few years, there has been evidence to suggest that a substantial proportion of ovarian cancer may start in the fallopian tubes, although some cancer clearly arises in the ovary. As a result, removal of both fallopian tubes (called โbilateral salpingectomyโ) has been suggested as an interim procedure to reduce risk in BRCA …
Permanent link to this article: https://inheritedcancer.net/2nlw2013/
ICARE Newsletter Winter 2013
The Selection of Chemotherapy in BRCA Patients with Pancreatic Cancer
ICARE Newsletter Winter 2013
The Selection of Chemotherapy in BRCA Patients with Pancreatic Cancer
Some evidence suggests that individuals with BRCA mutations who develop pancreatic cancer may benefit from specific chemotherapy regimens. In a recent review of this topic, Kim et al reported on a study of 5 patients with BRCA mutations (4 BRCA2 and 1 BRCA1) who were treated with a platinum-based chemotherapy regimen.1 Of these patients, 3 …
Permanent link to this article: https://inheritedcancer.net/1nlw2013/
ICARE Newsletter Winter 2013
Is Lynch Syndrome Associated with Breast Cancer?
ICARE Newsletter Winter 2013
Is Lynch Syndrome Associated with Breast Cancer?
The cancer spectrum typically seen in individuals with Lynch Syndrome includes cancers of the colon, endometrium, ovary, stomach, and other cancers (including cancer of the renal pelvis, ureter, small bowel and pancreas). The issue of whether breast cancer risk is elevated in those with Lynch syndrome has been controversial, with conflicting results between various studies. …
Permanent link to this article: https://inheritedcancer.net/3nlw2013/
ICARE Newsletter Summer 2012
Ask the Expert: What are the risks of hormone replacement therapy (HRT) on breast cancer risk in women with BRCA mutations?
ICARE Newsletter Summer 2012
Ask the Expert: What are the risks of hormone replacement therapy (HRT) on breast cancer risk in women with BRCA mutations?
The following questions were addressed by Drs. Pal and Lancaster at the Moffitt Cancer Center: Q. What are the risks of hormone replacement therapy (HRT) on breast cancer risk in women with BRCA mutations? A. Concern about HRT in BRCA carriers is its potential to raise the risk of breast cancer, as seen in the …
Permanent link to this article: https://inheritedcancer.net/4nls2012/
ICARE Newsletter Summer 2012
New Study Suggests Breast Cancer Risk for Non-Carriers of Family-Specific BRCA Mutations Is Not Increased
ICARE Newsletter Summer 2012
New Study Suggests Breast Cancer Risk for Non-Carriers of Family-Specific BRCA Mutations Is Not Increased
Data from a population-based study was recently reported to estimate breast cancer risk among family members who tested negative for a known BRCA1/2 family mutation (i.e., non-carriers). The study included 3047 women diagnosed with breast cancer. Results from the study indicated there was no increased risk for breast cancer in non-carriers as compared to family …
Permanent link to this article: https://inheritedcancer.net/3nls2012/
ICARE Newsletter Summer 2012
Emerging Cancer Panels for Testing Patients for Inherited Cancer Predisposition
ICARE Newsletter Summer 2012
Emerging Cancer Panels for Testing Patients for Inherited Cancer Predisposition
Genetic testing for inherited cancer predisposition is typically performed by testing for one condition at a time. However, with the tremendous advances in genetic testing technologies over the last few years, the cost of testing has plummeted. To put this into perspective, the first human genome cost 2-3 billion dollars to sequence and took over …
Permanent link to this article: https://inheritedcancer.net/1nls2012/